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ERIC RICHARD BUCK. Role of protein kinase phosphorylation on SERT
oligomerization: a novel mechanistic view. (Under the direction of SAMMANDA
RAMAMOORTHY).
The serotonin transporter (SERT) is the primary mechanism for the termination of
synaptic signaling. It is of clinical relevance because it is a high-affinity target for
therapeutics such as anti-depressants (SSRIs) and drugs of abuse such as cocaine,
amphetamine, and 3,4 methylenedioxymethamphetamine (ecstasy). It is also seen as a
protein potentially involved in the etiology underlying disorders such as clinical
depression, autism, anxiety-related disorders, obsessive compulsive disorder, and
anorexia nervosa among others. SERT has also been found to be a target of protein
kinases that exert their effects through phosphorylation. For example, activation of
protein kinase C (PKC) decreases SERT uptake of serotonin (5-HT) by increasing
internalization of SERT from the plasma membrane. Conversely, phosphorylation of
SERT by protein kinase G (PKG) appears to increase SERT uptake of 5-HT from the
synapse. It has also been thought that oligomerization of SERT is a necessary component
of endoplasmic reticulum (ER) exocytosis and plasma membrane expression. However,
there has been no common tie between these two very important processes of SERT
regulation. In this study, we examined regulation of SERT phosphorylation's effect on
SERT oligomerization.
Our results indicated that phosphorylation of SERT by kinases that stimulate 5HT uptake, p38 mitogen-activated protein kinase (MAPK) and PKG decrease SERT
oligomerization in HEK-293 cells. We also identified the putative phosphorylation site
xi

ofSERT for PKG. PKC however showed the opposite effect by increasing SERT
oligomerization upon activation with phorbol esters. In this study we also show that
phosphorylation is a potential mechanism for regulating the oligomeric state of SERT
using site-directed mutagenesis at a putative site in SERT phosphorylated by PKG.
Lastly, we show that human mutant polymorphisms found in patients with obsessivecompulsive disorder and other serotonin-related disorders, that have been shown to
increase 5-HT uptake by SERT, appear to decrease the homo-oligomeric complex of
SERT much like PKG and p38 MAPK. Lastly, we show that oligomerization is
necessary for correct protein expression and that physiologically relevant concentrations
of cocaine appear to increase SERT oligomerization. These results show for the first
time that the oligomerization status of SERT can be regulated by protein kinases.

xii

Chapter I.

GENERAL INTRODUCTION

1.1. Properties and Identification of Monoamine Transporters

Effective neuronal communication in the brain requires precIse and dynamic
regulation of neurotransmitter concentrations.

The monoamines, dopamine (DA),

norepinephrine (NE), and serotonin (5-HT), act as neurotransmitters in peripheral and
central nervous (PNS and eNS) in a variety of physiological (cognitive, autonomic,
reward-reinforced learning; and emotional) functions (Bunney, Sesace et al. 1987; Nicoll,
Madison et al. 1987; Fozzard 1989; Jacobs and Fornal 1991; Jacobs and Azmitia 1992;
Goldstein 1995) At the molecular level, monoamine signaling is dynamically regulated
by a diverse set of macromolecules including biosynthetic enzymes, secretory proteins,
ion channels, pre- and post-synaptic receptors, and transporters.

Structure, Function, and Pharmacology of Monoamine Transporters
The uptake of DA, 5-HT, and NE following release into the nerve terminals
through monoamine transporters is the principal process for termination of respective
monoaminergic (dopamanergic, serotonergic, and noradrenergic) neurotransmission. The
high-affinity plasma membrane dopamine transporter (DAT), norepinephrine transporter
(NET), and serotonin transporter (SERT) dictate the concentration, duration, and
magnitude of postsynaptic responses. Several different types of cell-surface receptors
exist to confer the specific actions of DA, 5-HT, and NE on target cells (Glennon and
Dukat 1995). However, the extracellular clearance of DA, 5-HT, and NE is carried out
by only one form (Ramamoorthy, Bauman et al. 1993) of DAT, SERT, or NET,
respectively, in the brain and periphery (Blakely, Berson et al. 1991; Hoffman, Mezey et
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al. 1991; Lesch, Wolozin et al. 1993). Monoamine transporters belong to the Na+fer
dependent gene family.

-

The amino acid sequence predicts the presence of 12

hydrophobic transmembrane domains with cytoplasmic NH2 and eOOH termini. Also,
the amino acid sequence reveals several potential phosphorylation sites for multiple
kinases in the cytoplasmic domains (Ramamoorthy, Bauman et al. 1993).

The

translocation ofamines by amine transporter requires Na+ and cr in the external medium.
Monoamine transporters are the high-affinity targets for various therapeutic agents and
substances of abuse (Ramamoorthy, Bauman et al. 1993). The critical role of monoamine
transporters for normal brain function is underscored by the wide range of drugs that
target monoamine transporters, including medications for depression, attention deficit
hyperactivity disorder (ADHD), smoking, addiction, obsessive-compulsive disorder, and
sleep disorders.

The majority of these drugs interfere with the transporter-mediated

clearance of extracellular biogenic amine neurotransmitters.

An ensuing surge of

extracellular monoamines activates monoamine receptors and triggers a cascade of
molecular and cellular events to produce therapeutic benefit.
1.1.1

The serotonin transporter

The monoamine transporter serotonin (5-hyrdoxytraptamine, 5-HT) plays an
important role as a neuromodulator in adult central and peripheral nervous system
regulating a variety of different physiological processes including mood, sleep, sexual
drive, appetite, memory, thyroid function, gastrointestinal motility, vasoconstriction, and
addiction (Fozzard 1989; Jacobs and Azmitia 1992).

The uptake of synaptic 5-HT

through Na-fCr -dependent SERT is the principal process of terminating serotonergic
neurotransmission. Though more than 15 different types of cell-surface receptors exist to

.
.;
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confer the specific actions of 5-HT on target cells (Glennon and Dukat 1995), a single
gene (Ramamoorthy, Bauman et al. 1993) encoding SERT appears to be responsible for
extracellular 5-HT clearance in the brain and periphery, SERT is mapped to human
chromosome band 17 q 11.1-q 12 (Blakely, Berson et al. 1991; Hoffman, Mezey et al.
1991; Lesch, Wolozin et al. 1993). In addition to serotonergic neurons, SERTs are also
expressed in platelets (Rudnick 1977; Lesch, Wolozin et al. 1993), placenta (Balkovetz,
Tiruppathi et al. 1989), intestinal crypt epithelia (Wade, Chen et al. 1996), adrenal
chromaffin cells (Tecott, Shirom et al. 1995; Schroeter, Levey et al. 1997), mast cells
(Hoffman, Mezey et al. 1991; Miller and Hoffman 1994), medullary thyroid carcinoma
cells (Clark, Lanigan et al. 1995), thyroid follicular cells (Tamir, Hsiung et al. 1996), and
lymphocytes (Lesch, Bengel et al. 1996; Faraj, Olkowski et al. 1997). While clearance of
synaptic extrasynaptic 5-HT appears to be the principal function of SERTs, certain cells,
notably platelets, utilize SERTS to acquire 5-HT from the extracellular environment for
subsequent release, involved in the process of platelet activation (Cirillo, Golino et al.
1999; Musselman, Marzec et al. 2002). Platelets and 5-HT neurons share many common
properties, including vesicular monoamine transporters (VMATs), 5-HT release,
biochemistry, identical SERT sequences, and 5-HT receptors (Owens and Nemeroff
1994). Therefore, platelets have been widely used as a peripheral indicator of central 5HT metabolism and SERT function in psychiatric disorders and vascular diseases in
which 5-HT has been implicated (Meltzer, Arora et al. 1981; Wirz-Justice 1988). In the
lung, SERTs efficiently clear plasma-borne 5-HT and regulate blood 5-HT levels with the
help of platelets.

4

Altered serotonergic neurotransmission and 5-HT have long been associated with
psychiatric disorders, including depression, suicide, impulsive violence, and alcoholism
(Heinz, Mann et al. 2001; Hahn and Blakely 2002a). Reduced binding of SERT ligands
imipramine and paroxetine to brain and platelet SERTs in patients with depression and
suicide victims indicated that altered SERT function might contribute to aberrant
behaviors.

All SERT antagonists have been shown to be effective antidepressants.

Drugs that block SERT, including tricyclic antidepressants such as imipramine, and
selective serotonin reuptake inhibitors (SSRls) like fluoxetine (Prozac), paroxetine
(Paxil), sertraline (Zoloft), and citalopram (Celexa) are successfully used in the treatment
of depression.

SSRls rapidly inhibit the uptake of 5-HT.

However, the therapeutic

efficacy of antidepressants develops slowly during several weeks of continuous
treatment.

The therapeutic efficacies of antidepressant drugs have been realized for

years, however, current knowledge regarding their mechanisms of action remains
incomplete.

Because it has been well recognized that treatment response to

antidepressants generally requires two or more weeks, studies on long-term adaptive
changes have been focused on regulation of receptors, transcription factors, and kinases.
SERT antagonists, including antidepressants and cocaine, limit clearance of neuronally
released 5-HT signaling, and hence neural plasticity.

Therefore, changes in SERT

kinetics and number will strongly influence the efficacy of antidepressants in the
treatment of depression.
Receptors that are known to influence amIne transporter function have been
implicated in depression as well as in animal models (Langer 1987; Stockmeier, Shapiro
et al. 1998; Maes, Van Gastel et al. 1999; Murphy, Wichems et al. 1999; Stockmeier, Shi
5

et al. 2002). Altered receptor expression, sensitivity to receptor ligands, and changes in
downstream signaling cascades have been demonstrated in antidepressant drug-treated
animals. Chronic antidepressant administrations alter activity and expression of second
messenger-regulated

protein

kinases

such

as

protein

kinase

C

(PKC),

calcium/calmodulin-dependent kinase II (CamKII), protein kinase A (PKA) , mitogenactivated

protein

kinase

(MAPK)

as

well

as

expression

of cAMP-specific

phosphodiesterase 4A and 4B isoforms and CREB protein (Popoli, Vocaturo et al. 1995;
Popoli, Venegoni et al. 1997; Tadokoro, Kiuchi et al. 1998; Battersby, Ogilvie et al.
1999; Takahashi, Terwilliger et al. 1999; Consogno, Dorigo et al. 2000; Popoli, Brunello
et al. 2000). These neuronal adaptations could serve as molecular switches for amine
clearance in vivo by changing the degree of receptor sensitivity, and thus signals linked
to SERT regulation. Some examples below describe how receptor-linked regulation of
SERT may playa role in depression and antidepressant treatments and vice versa.
Presynaptic inhibitory u2-adrenoreceptors are located on serotonergic nerve
endings, and endogenous NE is able to control the release and uptake of 5-HT (Ansah,
Ramamoorthy et al. 2000).

Decreased platelet u2-adrenoreceptor density and

dysregulation of nerve terminal u2-adrenoreceptor density and sensitivity have been
shown in depressed patients (Maes, Van Gastel et al. 1999). Genetic deletion of the U2adrenoreceptor in mice renders animals to mimic depression, suggesting a role for U2adrenoreceptor in the modulation of depression and anxiety (Schramm, McDonald et al.
2001). Receptors for u2-adrenoreceptor, adenosine, histamine, and 5-HT also regulate 5HT uptake (Launay, Bondoux et al. 1994; Miller and Hoffman 1994; Ansah,
Ramamoorthy et al. 2000).

Chronic antidepressant treatment increases expression of
6

brain-derived growth factor (BDNF), BDNF receptors, and TrkB receptor (the receptor
target of BDNF) function (Morinobu, Nibuya et al. 1995; Nibuya, Morinobu et al. 1995;
Russo-Neustadt, Beard et al. 2000).

BDNF produces antidepressant-like behavioral

effects and increases serotonergic neurotransmission (Celada, Siuciak et al. 1996; Altar
1999; Shirayama, Chen et al. 2002). BDNF, but not nerve growth factor (NGF), has been
shown to regulate SERT expression in B lymphocytes, suggesting the role of BDNF in
functional SERT expression (Mossner, Daniel et al. 2000). Evidence shows that BDNF
and activation of TrkB receptors increases 5-HT clearance by increasing SERT activity in
the rat hippocampus (Daws, Gerhardt et al. 1999; Daws, Gould et al. 2000).

Mice

lacking SERT have altered expression and function of 5-HT1a and 5-HTlb receptors
(Fabre, Beaufour et al. 2000). On the other hand, mice lacking the 5-HT1a and 5-HT1b
receptors show altered expression of SERT (Ase, Reader et al. 2001). Thus, elevated
extraneuronal 5-HT could influence 5-HT1a and 5-HT1b receptor signals, and hence
SERT activity. Substance P (SP) and substance Preceptor (NK-l) have been implicated
in the pathophysiology of depression (Rupniak and Kramer 1999; Lieb, Ahlvers et al.
2002).

Furthermore, genetic deletion and pharmacological blockade of NKI receptor

decrease depressive behaviors and increase serotonergic activity (Rupniak, Carlson et al.
2001; Bilkei-Gorzo, Racz et al. 2002), suggesting the serotonergic system as a potential
target for effects of SP on depression-related behaviors (Haddjeri and Blier 2001;
Rupniak, Carlson et al. 2001; Santarelli, Gobbi et al. 2001). Reduction of SP in the rat
brain after chronic antidepressant treatment (Shirayama, Mitsushio et al. 1996;
Shirayama, Chen et al. 2002) raises the possibility that the degree of NKI receptor
regulating SERT function may be altered after chronic exposure to antidepressants.
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1.1.2

The Norepinephrine Transporter
The noradrenergic system modulates attention, alertness, arousal, and vigilance.

Noradrenergic signaling is intimately linked with behavioral arousal (Astier, Van
Bockstaele et al. 1990) and is affected in stress-related paradigms linked to depression
(Pavcovich, Cancela et al. 1990). NE is an important chemical messenger in the nervous
system and regulates affective states, learning and memory, and endocrine and autonomic
functions. It has been implicated in depression, aggression, addiction, and cardiac and
thermal regulation. NE acutely inhibits nociceptive transmission mediated by substance
P (NK-lr), potentiates opioid analgesia, and underlies part of the antinociceptive effects
of tricyclic antidepressants and psycho stimulants (Holden and N aleway 2001; Jasmin,
Tien et al. 2002).

NET regulates noradrenergic signaling in the CNS and PNS by

mediating the clearance of NE and is an important target for antidepressants and
psycho stimulants (Axelrod and Kopin 1969; Iversen 1978; Pacholczyk, Blakely et al.
1991; Amara and Arriza 1993). The importance of NET to NE homeostasis suggests a
role for NET in disorders of both central and autonomic nervous systems. Involvement
of noradrenergic systems in mood disorders is suggested by the evidence that depression
is accompanied by altered indices of noradrenergic function and that effective
antidepressants enhance extracellular NE levels (Ressler and Nemeroff 1999; Ressler and
Nemeroff 2001). Furthermore, NET-binding sites are decreased in brains of patients with
major depression (Klimek, Stockrneier et al. 1997). The activation and sensitization of
NE systems in response to stress suggest that NE may play a role in disorders triggered
by early life trauma, including depression and Post-Traumatic Stress Disorder (PTSD)
(Heim and Nemeroff 2001). NE also plays an important role in attention, learning and
8

memory, and is hypothesized to contribute to ADHD (Biederman and Spencer 1999).
Stimulant drugs used to treat ADHD act on both the NET and the DAT, and atomoxetine,
which selectively targets NET, is also effective in treating ADHD. The activity of NET
at postganglionic sympathetic nerve terminals, especially in the heart, is impacted in
diseases of the cardiovascular system (Blakely 2001; Robertson, Flattem et al. 2001).
Diminished NE uptake sites and activity have been observed in hypertension, diabetes,
cardiomyopathy, and heart failure. Ischemia-induced efflux of nonvesicular, cytoplasmic
NE via NET may also contribute to fatal arrhythmias (Hahn and Blakely 2002b). NETs
are also expressed in peripheral tissues such as adrenal glands, vas deferens, and placenta.
NET is the only catecholamine transporter present in the placenta and is thought to shield
the fetus from fluctuating catecholamine levels in the maternal circulation. Analogous to
the brain, blockade of placental NET by cocaine may result in elevated catecholamines in
the maternal circulation. It is likely that pregnancy complications such as pre-term birth,
spontaneous abortion, and abruption placenta association with maternal cocaine abuse
relate to changes in the placental vascular physiology resulting from altered
catecholamine signaling. DA affinity for NET is higher compared with its affinity for
OAT, and NET density in the prefrontal cortex of the brain is higher than DAT density
(Hom 1973; Giros, Wang et al. 1994; Eshleman, Carmolli et al. 1999; Moron,
Brockington et al. 2002). NET -knockout (KlO) mice do not effectively clear DA in the
frontal cortex, underscoring the NET as a DA carrier in this brain region (Moron,
Brockington et al. 2002), and amphetamine reportedly releases DA from noradrenergic
neurons in the prefrontal cortex. NET is poorly expressed in the striatum and robustly
expressed in the frontal cortex (Shoblock, Maisonneuve et al. 2004). Thus, DAT/NET

9

ratios in discrete brain regions are likely to govern selective catecholamine transport as
well as selective drug effects on catecholamine transport.
depends on the test used.

The behavioral outcome

In studies on locomotion in NET KlO mice, it has been

suggested (Mead, Rocha et al. 2002) that differences in baseline locomotion should be
taken into account interpreting the observed psychostimulant supersensitivity (Xu,
Gainetdinov et al. 2000) and reduced cocaine sensitivity (Mead, Rocha et al. 2002).
While these studies indicate a role for the NET in the acute drug effect, the NET is not a
prerequisite for the locomotor effect as opposed to the DAT that is critical as shown by
the lack of effect of cocaine or amphetamine in DAT KID mice (Giros, Jaber et al. 1996;
Mead, Rocha et al. 2002).

In contrast, in cocaine self-administration studies, likely

measuring cocaine's reinforcing

effect~

NET becomes a major contributor in the absence

of DAT. Thus, while cocaine self-administration in DAT KJO mice is intact (Rocha,
Faumagalli et al. 1998), DA is cleared by NET in DAT KlO animals (Moron,
Brockington et al. 2002). In support of this notion, cocaine and amphetamine increased
dialysate DA in the nucleus accumbens of DAT KlO mice as did the specific NET
blocker reboxetine; selective blockade of DAT by GRR 12909 in DAT KlOx had no
effect on nucleus accumbens DA (Carboni, Spielewoy et al. 2001). It appears therefore
that cocaine or amphetamine can act on NET, which takes over the clearance of DA in
the nucleus accumbens when DAT is absent in DA T KlOx. However, more infonnation

is needed to fully understand the mechanism as desipramine did not enhance DA uptake
measured in vitro by voltammetry in the nucleus accumbens of DAT KlOs (Budygin,
John et al. 2002).
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1.1.3

The Dopamine Transporter
DA signaling regulates many critical functions such as movement, emotion, and

cognition (Carlsson, Waters et al. 2001; Greengard 2001). DAT terminates dopaminergic
neurotransmission by re-uptake of DA in presynatpic neurons and plays a key role in DA
recycling. DAT can also provide reverse transport of DA under certain circumstances.
Psycho stimulants such as cocaine and amphetamine are drugs used for ADHD such as
methylphenidate exert their actions via DAT (Sulzer, Chen et al. 1995; Sora, Wichems et
al. 1998). Recent molecular and pharmacological analyses using monoamine transporter-

KID mice have confirmed the physiological importance and requirement of presynatpic
amine transporter expression for normal transmitter clearance, presynaptic transmitter
homeostasis, postsynaptic, and drug responses (Rioux, Fabre et al. 1999; Xu, Gainetdinov
et al. 2000; Carboni, Spielewoy et al. 2001). In particular, functional loss of DAT either
through pharmacological inhibition (Kula and Baldessarini 1991; Giros, EI Mestikawy et
al. 1992) or through gene knockout (Giros, Jaber et al. 1996) results in profound physical,
physiological, and behavioral changes.
DAT not only functions as a carrier for DA but also mediates other processes,
adding another level of complexity to its potential role in neuropsychiatric diseases. In
the substantia nigra, DAT can regulate DA release, previously thought to be the domain
of D2 DA autoreceptors. Originally discovered in DAT-expressing cells, DAT produces
at least three types of ion channel-like conductances (Sonders, Zhu et al. 1997; Ingram,
Prasad et al. 2002). In the substantia nigra, substrate transport by the DAT initiates an
excitatory DAT -mediated current, cell depolarization, and consequent augmentation of
somatodendritic DA release (Falkenburger, Barstow et al. 2001; Ingram, Prasad et al.
11

2002). DAT-mediated regulation of DA release differs from the O 2 autoreceptor control
of release. In the presence of DA, DAT promotes DA release, whereas D2 autoreceptor
attenuates release. DAT -mediated DA release is triggered at relatively low OA levels,
whereas D2 autoreceptors control of DA release requires significantly higher DA
concentrations (Ingram, Prasad et al. 2002).

Finally, DAT substrate clearance (and

associated ion conductances) results in OA-neuron depolarizations and increased
neuronal firing rate, even if 02 receptor are blocked (Mortensen and Amara 2003). DAT
control of DA release is region specific.

In the striatum, DA clearance is a primary

function of the DA T, whereas in the substantia nigra the DAT regulates extracellular DA
levels by controlling both clearance and release. In DA terminal regions, D2-receptor
activation has been reported to enhance OAT function, adding another autoreceptormediated mechanism in regulating extraneuronal DA levels (Wu, Reith et al. 2002;
Gulley and Zanheiser 2003). Evidence for the critical and brain region-specific role of
the DAT in regulating DA neurotransmission and presynaptic homeostasis comes from
targeted deletion of the DAT gene in mice. In comparison with wild-type controls, DAT
mutant mice exhibit significant phenotypic transformations, including hyperactivity,
small size, skeletal abnormalities, pituitary hypoplasia, impaired care by females for their
offspring, cognitive and sensorimotor gating deficits, and sleep dysregulation.

The

striatum of the mutant mice adapts by reducing the DA-synthesizing enzyme tyrosine
hydroxylase, vesicular DA stores, stimulated DA release and Dl and D2 (but not D3)
receptor densities and function [for review, see (Gainetdinov and Caron 2003)]. The
extreme changes in DA-signaling systems of the striatum are not replicated in the frontal
cortex, and indeed, this brain region retains normal dopaminergic systems. Because DAT
l
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density in the frontal cortex is low as DA uptake proceeds normally in the frontal cortex
DAT-KiO mice, it is unlikely that drug-induced blockade of DAT is a significant
contributor to elevated DA levels in the prefrontal cortex. In the normal brain, the frontal
cortex expresses much lower levels of the DAT and DA autoreceptors, stores less DA,
and relies more on DA synthesis than on vesicular recycling for DA release.

These

contrasting cortical and striatal DA regulatory processes have implications for ADHD.

1.2

Regulation of Monoamine Transporters

Monoamine Transporters and Their Functional Regulation
Monoamine transporters in general, function by sequestering monoamines from
specific nerve terminals. However, in several brain regions and under certain conditions,
monoamine transporter functions can overlap (Cases, Lebrand et al. 1998; Pan, Gembom
et al. 2001; Moron, Brockington et al. 2002). Pharmacological and behavioral studies in
genetic animal models with targeted disruption of monoamine transporters suggest
functional overlap between these transporters.

Consequently, pharmacological and

physiological characterizations to distinguish their role in psychiatric illnesses and drug
abuse require proper understanding of the mechanisms regulating monoamine transporter
function.
A range of physiologic, pharmacologic, and activity-dependent mechanisms can
regulate monoamine transporters acutely.

Changes in the transporter activity or

expression will have a significant impact on the duration and concentration of
monoamines present in and outside the synaptic cleft. These changes, resulting in the
regulation of transporter function, in tum would influence pre- and postsynaptic
I
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responses to released monoamines. Several studies suggest the function at the level of
gene transcription and translation (long-term or chronic regulation requiring hours or
days) or posttranslational protein modifications (short-term or acute regulation requiring
seconds to minutes) (Blakely, Ramamoorthy et al. 1997; Ramamoorthy 2002; Jayanthi
and Ramamoorthy 2005).
1.2.1

Chronic Regulation of Amine Transporters
Structural analysis of transporter gene promoter regIons reveals a number of

canonical transcription-binding sites that may be important in controlling the responses of
the transporter gene to regulatory factors (Lesch, Balling et al. 1994; Kawarai, Kawakami
et al. 1997; Fritz, Jayanthi et al. 1998; Flattem and Blakely 2000; Murphy, Lerner et al.
2004; Kelada, Costa-Mallen et al. 2005; Marziniak, Mossner et al. 2005).

Relevant

investigations performed on JAR cells have shown that activation of cAMP-dependent
(mimicked by cholera toxin, forskolin, dibutyrl cAMP) and -independent pathways
(mimicked by staurosporine and

interleukin-1~)

increases 5-HT uptake. Increases in 5-

HT uptake require prolonged stimulation as well as messenger RNA and protein
synthesis (Ramamoorthy, Ramamoorthy et al. 1995b; Ramamoorthy, Ramamoorthy et al.
1995c). Similarly, angiotensin II increases NET activity at the level of regulating NET
gene transcription (Lu, Yu et al. 1996).
1.2.2

Acute Regulation of Amine Transporters
Amino acid sequence analysis ofSERT, OAT, and NET proteins reveal numerous

consensus sites for protein kinases as well as putative interactive motifs in cytoplasmic
domains suggesting that second messengers are able to play a role in post-translational
l
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regulation of monoamine transporters. Before the cloning of monoamine transporters,
evidence suggested a pivotal role for second messenger-linked pathways in the acute
modulation of neurotransmitter uptake (Ramamoorthy 2002). Potential pathways linked
to second messenger-linked pathways might regulate transporter function acutely.
Multiple reports have demonstrated a capacity of native and heterologously expressed
amine transporters to be regulated rapidly following acute elevation/depletion of
intracellular Ca2+, treatment with calmodulin inhibitors, or via activation of PKC,
NOS/cGMP, and MAPK pathways. Since the second messenger-linked pathways noted
above can be

linked to

presynaptic

receptors,

these

pathways

may provide

positive/negative feedback mechanisms in control of amine clearance in vivo (Blakely,
Ramamoorthy et al. 1998; Ramamoorthy 2002; Melikian 2004; Zahniser and Sorkin
2004; Blakely, Defelice et al. 2005; Jayanthi and Ramamoorthy 2005).

Mechanisms o/Short-Term Monoamine Transporter Regulation
Regulation of transport function can occur directly by phosphorylation of
transporter proteins.

Phosphorylation of transporter proteins might in tum change

intrinsic transport activity, turnover rate, plasma membrane insertion by modulating
exocytic fusion and/or sequestration from the plasma membrane by modulating endocytic
machinery. Alternatively, transporters can be regulated through their association with
other interacting proteins by phosphorylation-dependent or -independent pathways.
Substrate or antagonist binding may also modulate transport activity via its influence on
transporter phosphorylation, trafficking, and interaction with transporter-interacting
proteins.

Post-translational modifications such as glycosylation, phosphorylation, and

ubiquitination regulate monoamine transporter function and expression levels (Vaughn,
I
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Huff et al. 1997; Ramamo orthy , Giovanetti et al. 1998; Jayanthi, Samuvel et al. 2004;
Jiang, Jiang et al. 2004; Li, Chen et al. 2004; Miranda, Wu et al. 2005). In addition,
variations in monoamine transporter gene sequences known as polymorphisms may also
alter transporter expression levels, activity and/or regulation. Recent studies demonstrate
that the activity and expression of monoamine transporters are regulated by
phosphorylation and dephosphorylation of transporter proteins.

Thus, monoamine

transporters are dynamically regulated by intracellular and extracellular regulation of the
phosphorylation state, which in tum significantly impacts the duration and concentration
of monoamines present in and outside the synaptic cleft.
1.2.3

Regulation of Monoamine Transporter Trafficking

Among various stimuli that acutely regulate monoamine transporters, the majority
regulates transport function by altering transporter surface expression.

Activation of

PKC pathways by phorbol esters reduces 5-HT, NE, and DA transport capacity and the
number of binding sites on the cell surface [for reviews, see (Gulley and Zanheiser 2003;
Mortensen and Amara 2003)]. Presynaptic receptor activation such as NKI activation
leads to activation of PKC, and subsequently downregulation of DAT and NET. DA
itself regulates DAT, directly by downregulating surface expression, or indirectly by
upregulating the DAT via D2 dopamine autoreceptors [for review, see (Wu, Reith et al.
2002; Gulley and Zanheiser 2003)]. Using PKC isoform-specific inhibitors as well as coexpression studies reveals the involvement of classical

PKC~II

in DAT downregulation.

DAT function is also regulated by arachidonic acid, ethanol, tyrosine kinase
activator/inhibitors, and nitric oxide (Lonart and Johnson 1994; Zhang and Reith 1996;
Mayfield and Zanheiser 2001). Analogous PKC-mediated transporter redistribution has
4
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been detected for NET and SERT (Kitayana, Dohi et al. 1994; Zhang, Coffey et al. 1997;
Apparsundaram, Galli et al. 1998a; Apparsundaram, Schroeter et al. 1998b; Jayanthi,
Samuvel et al. 2004). In transformed cell line SK-N-SH cells, where NET is expressed
endogenously, activation of muscarinic acetylcholine receptors also results in NET downregulation. Moreover, inhibition of PKC by antagonists abolishes PKC-mediated effects
but produces only partial blockade of methacholine-mediated effect. PKC activation and
pathways dependent on mobilization of Ca2+ stores are involved in muscarinic receptormediated NET regulation (Apparsundaram, Galli et al. 1998a). Thus, studies show the
existence of PKC-independent regulatory pathways supporting NET surface expression
and/or intrinsic transporter catalytic activity.
Downregulation of transporters by PKC may be present but could occur across a
different time frame. Indeed, recent studies using natively expressed SERT in platelets
show diminished catalytic activity before an enhancement of SERT endocytic rate that
ultimately reduces cell-surface SERT expression. Thus, these findings suggest that PKC
activation regulates SERT in bi-phasic manner, where the initial phase of inhibition
occurs independent of trafficking and the later phase characterized by an enhanced
endocytosis.
Hormones and trophic factors acting through tyrosine kinase-linked receptors
have also been implicated in monoamine transport regulation.

Insulin regulates NE

transport (Boyd, Clarke et al. 1985; Boyd, Clarke et al. 1986; Figelwicz, Szot et al. 1993;
Figelwicz, Szot et al. 1994; Figelwicz, Patterson et al. 1999). Recent work also shows
regulation of DAT functional by insulin, presumably through PI3-kinase (which is
activated by the insulin receptor) (Carvelli, Moron et al. 2002) and downstream Akt
I
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(Garcia, Wei et al. 2005); this presumably plays a role in effects of food restriction on
psycho stimulant reinforcement. In the case of NET, MAPKs are involved, differentially
regulating NET function by trafficking-dependent and -independent mechanisms
(Apparsundaram, Sung et al. 2001).
Not only NET (Apparsundaram, Sung et al. 2001) but also DAT (Carvelli, Moron
et al. 2002) and SERT (Zhu, Hewlett et aL 2004; Samuvel, Jayanthi et al. 2005) are
regulated by MAPKs. While studies on DAT (Moron, Zakharova et aL 2003) and SERT
(Samuvel, Jayanthi et al. 2005) implicate MAPK effects on transporter trafficking, other
studies on NET and SERT indicate modulation of transporter catalytic activity.

p38

MAPK-mediated SERT redistribution involves enhanced plasma membrane insertion of
the transporter (Samuvel, Jayanthi et al. 2005).

Numerous studies have indicated

alterations in 5-HT levels, SERT binding sites, and serotonergic neuronal firing in
response to numerous stressors (Chaouloff, Berton et al. 1999) such as anisomycin-D,
ultraviolet light, and free radicals. Thus, the regulation of SER'r by p38 MAPK, a stressinduced kinase, may provide a novel presynaptic mechanism in maintaining appropriate
synaptic 5-HT levels during stressful conditions. Several studies indicate that SERT is
upregulated by a cGMP/PKG-mediated pathway through altered surface expression
(Miller and Hoffman 1994; Kilic, Murphy et al. 2003; Zhu, Hewlett et al. 2004).
Interestingly, MAPK effects on SERT intrinsic activity are also sensitive to PKG activity
(Zhu, Hewlett et al. 2004).

Thus, monoamine transporters are subjected to multiple,

interacting modes of kinase-dependent modulation via trafficking-dependent and
trafficking-independent mechanisms.
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1.2.4

Altered Transporter Phosphorylation
Recent studies on monoamine transporters reveal that changes in activity and

expression are regulated by transporter phosphorylation and dephosphorylation. Thus,
the transporters are dynamically regulated by intracellular and extracellular regulation of
phosphorylation states, which in tum should have a significant impact on the duration and
concentration ofmonoamines, present extraneuronally. DAT, SERT, and NET proteins
are phosphorylated in response to PKC activation (Vaughn, Huff et al. 1997;
Ramamoorthy, Giovanetti et al. 1998; Jayanthi, Samuvel et al. 2004).

SERTs are

phosphorylated following PKC and PKA activation and protein phosphatase 2A (PP2A)
inhibition. DAT proteins are also phosphorylated in transfected cells and synaptosomal
preparations following treatment with PKC activators and PP2A inhibitors (Huff, Vaughn
et al. 1997; Vaughn, Huff et al. 1997).

The PKC-dependent phosphorylation effect

shows a close temporal correlation with reduction in transport capacity (Ramamoorthy,
Giovanetti et al. 1998; Ramamoorthy and Blakely 1999).

SERT substrates and

antagonists influence PKC-dependent SERT phosphorylation and surface redistribution
(Ramamoorthy and Blakely 1999). Recent studies indicate that while PKC activation
increases SERT basal phosphorylation, p38 MAPK inhibition decreases SERT basal
phosphorylation, indicating a role for p38 MAPK-induced phosphorylation in constitutive
SERT expression (Samuvel, Jayanthi et al. 2005). More recently, investigations from our
laboratory identified a previously unidentified biphasic regulation of endogenous SERTs
expressed in platelets (J ayanthi, Samuvel et al. 2005). The findings from this study
suggest that PKC activation regulates SERT in a biphasic manner, where the initial phase
of inhibition occurs independent of trafficking and the later phase is characterized by and
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enhance endocytosis. The biphasic inhibition of SERT is accompanied by a sequential
phosphorylation of plasma membrane-resident SERT initially on serine residue(s) and
then on threonine residues( s), suggesting that the initial phosphorylation on serine
residues might be responsible for changes in the intrinsic properties andlor silencing of
SERT and that the phosphorylation on threonine residues later on might trigger
internalization of phosphorylated SERT.
DAT is phosphorylated on N-terminal serine residues (Foster, Paranusorn et al.
2002). The PKC-mediated internalization of monoamine transporters occurs in parallel
to enhance phosphorylation of the transporter.

Although the transporters undergo

phosphorylation in response to PKC activation or PP1/2A inhibition, it is not known
whether phosphorylation of the transporter leads to its internalization. However, recent
studies using phospho-site mutants of transporters provided positive as well as negative
correlations between phosphorylation and transporter functional regulation (Bonisch,
Hammermann et al. 1998; Whitworth and Quick 2001b; Granas, Ferrer et al. 2003; Lin,
Zhang et al. 2003). Studies demonstrate that tyrosine kinase activity is also critical in
maintaining NET (Apparsundaram, Sung et al. 2001), DAT (Doolen and Zanheiser
2001), and GAT (Law, Stafford et al. 2000; Whitworth and Quick 2001a) cell-surface
levels. Phosphorylation of YI 07 and Y317 on y-aminobutyric acid transporter (GATI) is
required for tyrosine kinase-mediated y-aminobutyric acid (GABA) transport regulation
(Whitworth and Quick 200Ia). Interestingly, the reciprocal relationship between PKCand tyrosine kinase-mediated GATI phosphorylation suggests that a balance between
these two states of phosphorylation may dictate relative abundance of GA Tl on the cell
surface (Quick, Hu et al. 2004).
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While a part of the N-terminal domain appears to interact with syntaxin lA
involved in PKC-mediated regulation (Sung, Apparsundarma et al. 2003), determinants
within the C-terminus of human NET (hNET) dictate NET trafficking, stability, and
activity (Bauman and Blakely 2002). Interestingly, nonclassical endocytic signals dictate
constitutive and PKC-regulated internalization of DAT (Holton, Loder et al. 2005;
Sorkina, Hoover et al. 2005). These signals are conserved in NET. However, it is not

known whether there is a relationship between NET phosphorylation and PKC-induced
transporter regulation. NET protein contains multiple consensus sites for several kinases
including PKC that are distinct from those present in DAT or SERT, and therefore, NET
may be regulated by mechanisms that are different than those ofDAT and SERT. Recent
work by our lab (Jayanthi, Annamalai et al. 2006) demonstrates that a PKC-site mutant of
hNET is resistant to PKC-mediated downregulation and phosphorylation. This study
provides the first evidence that phosphorylation of a PKC motif on a monoamine
transporter is linked to transporter internalization. In addition this PKC-site mutant of
hNET exhibits altered transport properties such as increased affinity for NE and
substrate-like ligand D-amphetamine and decreased affinity for inhibitory ligands such as
cocaine, desipramine, and nisoxetine. Phospho-site mutations could contribute to altered
NE transport process due to physical conformational changes occurring as the result of
mutation or the altered phosphorylation state itself.

Such changes can result in the

second intracellular loop reported altered ligand-binding properties attributed to structural
changes in the physical conformation of DAT protein (Goldberg, Beuming et al. 2003;
Uhl and Lin 2003; Fornes, Nunez et al. 2004; Loland, Granas et al. 2004). More recently
we have discovered a putative PKG phosphorylation site in SERT within intracellular
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loop-2 (IL2) which has been found to be correlated with an increase in SERT uptake of 5-

HI upon cGMP activation by various agonists. Such investigations would prove useful
in developing antidepressant drugs with higher efficacy and reduced potential side
effects.

1.2.5

Regulated Protein-Protein Interactions
Monoamine transporters can act as a single unit, self-associate, or bind to other

proteins. As described earlier, agents that maintain the phosphorylated state modulate
amine transporter activity. For example, inhibition of PPI/PP2A by okadaic acid (OA)
downregulates SERT, DAT, and NET activity. Phosphorylation state and regulation of
amine transporters is a balance between the actions and localization of protein kinases
and protein phosphatases.

The pronounced effect of PPI/PP2A inhibition on amine

uptake and amine transporter phosphorylation suggests the possible physical association
off PPI/PP2A as a regulatory complex with amine transporter proteins. Indeed, physical
complexes containing biogenic amine transporter and PP2Ac protein were recently
demonstrated (Bauman, Apparsundaram et al. 2000).

The SERTIPP2A complex is

disrupted by PP 1IPP2A inhibitors as well as PKC activators and can be stabilized by the
SERT substrate 5-HT, suggesting that modulation of SERT/phosphatase association is
involved in regulated transporter phosphorylation and trafficking. Similar transporter and
PP2Ac associations were found for DAT and NET proteins. Analogous to findings in
SERT studies, PP2Ac association with NET in vas deferens was also decreased by PKC
activation and PPI/PP2A inhibition.
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While direct phosphorylation and/or dephosphorylation of transporters by cellular
protein kinases and phosphatases is involved in the dynamic regulation and expression of
transporters, other integral membrane proteins also appear to play an important role in
trafficking and catalytic function of transporters.

The first evidence for the physical

association of GAT1 GABA transporter with (t)-SNARE protein syntaxin-1A as a
complex comes from studies by Quick and his coworkers (Deken, Beckman et al. 2000;
Horton and Quick 2001). DAT, SERT, and NET are also physically associated with
syntaxin-IA (Haase, Killian et al. 2001; Sung, Apparsundanna et al. 2003; Lee, Kim et
al. 2004; Samuvel, Jayanthi et al. 2005).

Using noradrenergic tissues such as vas

deferens and transfected cell lines, it was reported that syntaxin-1A is found in NET
immunoprecipitates (Sung, Apparsundanna et al. 2003).

Activation of PKC or

phosphatase inhibition decreases sytaxin-IA level with NET. Altering intracellular Ca2+
also regulates syntaxin-IAINET interaction. P38 MAPK inhibition and PKC, activation
decreases SERT and syntaxin-l A interactions in rat brain synaptosomes (Samuvel,
Jayanthi et al. 2005). Together these findings suggest an important role for syntaxin-IA
in neurotransmission by regulating both transmitter release and reuptake.
DAT interacts with several regulatory proteins, including a-synuclein, syntaxinlA, and PICK1.

Monoamine transporters also exist in oligomeric forms, but their

functional significance is not known (Schmid, Scholze et al. 2001; Norgaard-Nielsen,
Norregaard et al. 2002; Torres, Carneiro et al. 2003). Certain intracellular proteins such
as PICK1 (protein-1 that interacts with C-kinase) and a-synuclein also interact with DAT
to stabilize its cell-surface expression (Torres, Yao et al. 2001; Sidhu, Wersinger et al.
2004).

Signals following presynaptic receptor stimulation may influence transporter
I
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function and expression by regulating the stability of transporter heteromeric complexes.
Studies show interaction of PDZ domain-containing protein PICKI with C-terminal
cytoplasmic domains ofDAT and NET (Torres, Yao et al. 2001). Co-expression ofDAT
and PICKI enhances DAT activity and PICKI co-immunoprecipitation with DAr.
Confocal microscopy analysis reveals colocalization of both DAr and PICKI in
heterologous systems and in dissociated dopaminergic neurons. Since PICKl is a PKCbinding protein, it is possible that PICKl acts like an adaptor to bring PKC near OAT
proteins, which in tum could regulate PKC-evoked OAT phosphorylation, trafficking,
and function.

Such DAT and PKCPII interactions have been recently demonstrated

(Johnson, Guptaroy et al. 2005). a-synuclein is enriched in dopaminergic nerve terminals
and has been implicated in Parkinson's and other neurodegenerative disorders
(Polymeropoulos, Lavedan et al. 1997). a-synuclein binds directly to the C-terminal
region of OAT and facilitates plasma membrane clustering and increase in OAT activity
(Lee, Liu et al. 2001; Wersinger, Vernier et al. 2004). This study suggests that the asynucleinlDAT complex regulates normal dopaminergic neurotransmission and altered
interactions

may

result

In

abnormal

DAT

function

caUSIng

dopaminergic

neurodegeneration seen in Parkinson's disease. DAT also interacts with LIM domaincontaining adapter protein, Hic-5 (Carneiro, Ingram et al. 2002). Hic-5 is known to
interact with signaling molecules such as nonreceptor protein tyrosine kinases focal
adhesion kinase (F AK) and FYN. This raises the possibility that Hic-5 may be involved
in tyrosine kinase-mediated OAT regulation.
protein-protein interactions play an

Together, these studies indicate that

important role

phosphorylation, trafficking, and intrinsic activity.
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in influencing transporter

1.2.6

Substrates and Antagonists Effects on Monoamine Transporters
Amine transporter substrates and antagonists are known to regulate transporter

function and expression (Bernstein and Quick 1999; Munir, Correale et al. 2000; Quick
2002; Samuvel, Jayanthi et al. 2005). Since transporters are subjected to phosphorylation

by multiple kinase-dependent modulations, it is possible that substrates may also
influence transporter surface expression by regulating kinase-mediated transporter
phosphorylation.

For example, SERT substrates such as 5-HT, amphetamines, and

fenfl uramine and antagonists such as antidepressants and cocaine control PKC-dependent
SERT phosphorylation and surface redistribution (Ramamoorthy and Blakely 1999).
Transporting of SERT substrates, 5-HT, amphetamine, and fenfluramine protect SERT
from PKC-linked phosphorylation and sequestration.

The effect of 5-HT on SERT

dependent but not 5-HT receptor-dependent, and the nontransported ligands such as
cocaine and antidepressants block the effect of 5-HT.

Interestingly, amphetamines

substitute for substrates in suppressing PKC-mediated SERl' phosphorylation.

Such

action could override homeostatic transporter sequestration processes and provide for
psychostimulant sensitization by increasing the number of psychostimulant targets
available to a subsequent stimulus.

On the other hand, nonpermeant SERT ligands

including SSRIs and cocaine that prevent 5-HT permeation block the effect of 5-HT
uptake but also by shifting the cellular-distribution of SERT. D-Amphetamine, which is
also a substrate for SERT, increases SERT basal phosphorylation that is sensitive to p38
MAPK inhibition suggesting that p38 MAPK may govern substrate-mediated effects on
SERT basal phosphorylation (Samuvel, Jayanthi et al. 2005).
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NET proteins are downregulated following chronic treatment (3 days) with the
NET substrate NE, amphetamine, and antagonist desipramine, perhaps through changes
in protein expression and/or NET turnover (Zhu and Ordway 1997; Zhu, Shamburger et
al. 2000; Ordway, Jia et al. 2005).
OAT antagonists and substrates differentially modulate basal and PKC-mediated
OAT phosphorylation in rat brain synaptosomes and OAT-expressing cell lines. Acute
exposure to transporter substrates reduces DAT membrane expression, while brief
treatment with transporter blockers increases DAT cell-surface expression. In addition,
the regulation of DAT trafficking has been shown to tightly correlate with the functional
regulation of DA transport capacity.

Amphetamines trigger DAT internalization

(Saunders, Ferrer et al. 2000), and while acute cocaine exposure increases DAT surface
levels (Daws, Callaghan et al. 2002; Little, Elmer et al. 2002), amphetamine-induced
DAT internalization is blocked by cocaine (Saunders, Ferrer et al. 2000). This inverse
relationship between antagonist binding and substrate translocation suggest that various
transporter conformational states may promote or preclude their engagement with cellular
endocytic machinery, dictating transporter surface levels.
Substrate translocation or ligand occupancy may influence the equilibrium of
protein conformation required for transporter phosphorylation or transporter association
with other regulators. Thus, a feedback loop may exist, providing a mechanism by which
changes in extracellular neurotransmitter concentrations could rapidly modulate
neurotransmitter transport capacity.

This way, the control of transporter cell-surface

expression by its substrates or ligands would provide a novel homeostatic mechanism in
the neuron to fine-tune transport capacity to match demands imposed by fluctuating
26

levels of the neurotransmitter.

Signaling pathways linked to presynatpic auto- and

heteroreceptors could provide a positive/negative feedback control and provide a
mechanism by which changes in extraneuronal neurotransmitters could rapidly modulate
transport capacity of the transporter. Altered or inappropriate regulatory mechanisms
may contribute to transporter dysregulation described in psychiatric and other disorders.
Any disturbance in the homeostatic regulatory mechanism, for example by
antidepressants or psycho stimulants, would be predicted to alter the normative
physiological regulation of 5-HT levels and potentially produce pathological or
therapeutic effects.

Determining the mechanism by which transporter substrates and

blocker affect transporter cell-surface expression is certain to be important for the
development of new therapies for the treatment of psychiatric illnesses, drug abuse, as
well as other disease states such as ADHD and Parkinson's disease.
Monoamine Transporter in Addiction

Monoamine transporters are also of particular interest in the field of addiction
because they constitute high-affinity molecular targets mediating the cellular and
behavioral effects of psycho stimulants such as amphetamine and cocaine (Reith, Meisler
et al. 1986; Seiden, Sabol et al. 1993). Repeated use of certain transport inhibitors, such
as cocaine, can eventually lead to compulsive drug-seeking behavior.

Given the

importance of monoamine transmission in various aspects of addiction, and the profound
influence that monoamine transport has on the extracellular levels of monoamines, as
well as intracellular monoamine homeostasis, long-term changes in transporter level,
kinetics, or regulation would be expected to greatly influence spontaneous and druginduced behaviors. This possibility is clearly evidenced by the large effects on drug27

induced behaviors, as well as on neurotransmitter synthesis, storage, and release by
removing monoamine transporter genes in mutant mice (Giros, Jaber et al. 1996; Bengel,
Murphy et al. 1998; Rocha, Faumagalli et al. 1998; Sora, Wichems et al. 1998).
Receptors that are known to influence amine transporter functions, such as 5-HT 1B
(SERT), and D2 , opioid, or mGluR5 (OAT) have been implicated in cocaine sensitization
(Nestler and Aghajanian 1997; Pierce and Kalivas 1997; Thompson, Zapata et al. 2000;
Page, Peeters et al. 2001). Such changes in receptor-linked signaling cascades could
influence phosphorylation of transporters or associated proteins, and thereby transporter
activity.

Since the second messenger-linked pathway can be linked to presynatpic

receptors, these pathways may provide positive/negative feedback mechanisms in control
ofDA, 5-HT, and NE in vivo

1.2.7 Dysregulation of Amine Transporters in Human Disease
Biogenic amines 5-HT, DA, and NE control many behavioral and physiological
functions in the eNS and PNS. Altered amines as well as amine transporters have been
implicated in several psychiatric, neurodegenerative, and addictive disorders. Several
other diseases and neuropsychiatric disorders are also likely to have genetic contributions
from SERT, NET, and OAT. These include developmental disorders such as ADHD,
autism, sudden infant death syndrome (SIDS), and Tourette's syndrome as well as
equally complex disorders such as polysubstrate abuse, irritable bowel syndrome (IBS),
primary pulmonary hypertension (PPH), and myocardial infarction.
Two polymorphic regions, the long (I) and short (s) have been identified in the
SERT promoter. The long (I) variant is associated with increased 5-HT uptake, and the

,
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short (s) with low 5-HT uptake. The "s" variant plays a functional dominance over the
long allele.

SERT-linked promoter regions have been implicated in anxiety, mood

disorders, alcohol abuse, and other neuropsychiatric disorders.

The degree to which

SERT-linked promoter variants influence SERT expression in vivo is controversial, with
both supportive and contradictory evidence (Flattem and Blakely 2000; McCauley, Olsen
et al. 2004). A recent search for sequence variants in the SLC6A4 gene, encoding SERT,
uncovered 15 variants in genomic DNA from a population of 450 individuals in the DNA
Polymorphism Discovery Resource (Ozaki, Goldman et al. 2003). Of these, six were
synonymous and the remaining nine resulted in an amino acid changes (Thr3Ala,
Gly56Ala, Leu255Met, Ser293Phe, Pr0339Leu, Leu362Met, Ile425Val, Lys605Asn, and
Pro621Ser). Dennis Murphy of NIMH reported that two unrelated probands and their
family members with OCD contained the Ile425Val coding variant carried on the 5HTTLPRll/l background (Ozaki, Goldman et al. 2003).

In functional studies, this

variant has been found to exhibit elevated 5-HT uptake activity without any changes in
SERT surface expression and was insensitive to stimulation by nitric oxide donors in
transfected cells. Recently, Blakely's group identified several other human variants that
are linked to autistic disorder (Prasad, Zhu et al. 2005; Sutcliffe, Delahanty et al. 2005).
Human SERT variants T4A and G56A, failed to show 5-HT uptake stimulation when
tested with 8-Br-cGMP and anisomycin, typical of wild-type hSERT. Importantly, in a
physiologically relevant human cell model, such as Epstein-Barr Virus (EBV) ..
transformed lymphocyte natively expressing the most common of these variants
(Gly56Ala), a loss of 5-HT uptake stimulation by PKG and p38 MAPK activators was
observed.

Furthermore, HeLa cells transfected with the Gly56Ala variant exhibited
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elevated basal phosphorylated and, unlike wild-type SERI', could not be further
phosphorylation after 8-Br-cGMP treatment (Prasad, Zhu et al. 2005). On the basis of
these findings, it is hypothesized that obsessive compulsive disorder (OCD) and autistic
subjects carrying mutant SERT show elevated levels of SERT expression as if they were
being stimulated constitutively through a cGMP-linked pathway.
The hNET gene is a single-copy gene (SLC6A2) located on chromosome 16 and
(Hahn and Blakely 2002b) containing 16 exons. A number of hNET promoter, intron,
and coding region polymorphisms have been identified through both discovery-oriented
studies of hNET in various clinical populations or during the course of genome
sequencing efforts (Hahn and Blakely 2002b).

To date, approximately 20 non-

synonymous single nucleotide polymorphisms (SNPs), which result in amine acid
substitutions, have been reported in hNET. Many of these variants were derived from
psychiatric and cardiovascular phenotypes, yet only a limited number has been examined
for alterations in expression or function (Halushka, Fan et al. 1999; Runkel, Bruss et al.
2000; Stober, Meyer et al. 2000; Iwasa, Kurabayashi et al. 2001). In a familial form of
orthostatic intolerance, Blakely's laboratory identified a nonsynonymous hNET SNP that
produces the protein variant, A457P, a loss of function, dominant-negative transporter
that contributes to increased heart rate, high plasma NE levels, and reduced systemic NE
clearance.

This study demonstrates the impact of the hNET coding variant on NE

clearance contributing to increased heart rate, high plasma NE levels, and reduced
systemic NE clearance (Shannon, Flattem et al. 2000).

This study demonstrates the

impact of the hNET coding variant on NE clearance contributing to a human disease
condition. Another recent study from Blakely's laboratory revealed striking effects of
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these naturally occurring SNPs on transporter protein expression, substrate transport,
antagonist interaction, and regulation by kinase-mediated signaling pathways.

Of

particular interest are hNET F528C and hNET R121Q variants identified in some
cardiovascular phenotypes that showed altered regulation by the PKC-mediated pathway.
While F528C was insensitive, R121Q was more sensitive to PKC-dependent regulation
suggesting that similar mechanisms may underlie differences observed in both basal and
regulated transport (Hahn, Mazei-Robison et al. 2005). These findings signify the search
for underlying mechanisms of transporter regulation by signaling pathways in normal
physiology and pathophysiology.
Altered DAT function or density has been implicated in various types of
psychopathology, including depression, suicide, anxiety, aggression, and schizophrenia
(Eichelman 1990; Carlsson, Waters et al. 2001; Comings 2001; Meyer, Goulding et al.
2002).

Associations between DAT gene polymorphisms and human disorders with

possible links to the DA system, including ADHD and consequences of cocaine and
alcohol abuse, have been reported (Miller, De La Garza et al. 2001).

Although the

coding region of the human DAT gene contains very limited genetic variation, variants of
the DAT gene may exist, and possibly arise from RNA editing or via other mechanisms
(Miller, De La Garza et al. 2001). A repeat sequence in the 39-untranslated region (39URT) of the human DAT is associated with ADHD (Cook, Stein et al. 1995).

A

thorough examination of potential coding sequence variants in more than 150 unrelated
individuals free of neuropsychiatric disease, or with Tourette's syndrome, a diagnosis of
ethanol dependence, or ADHD (Vandenbergh, Thompson et al. 2000). The study did
reveal a low frequency of two naturally occurring human DAT variants, i.e. V55A and
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V382A (Vandenbergh, Thompson et al. 2000). In a subsequent report on COS cells
expressing these variants, V55A was shown to display a lower Km for DA uptake
compared with wild type, and V382 a lower Vmax (a dominant effect on expression
observed also in the present of wild type) as well as lower affinity of DA for DAT as
measured by inhibition of cocaine analog binding (Lin and UhI 2003). In a separate
study of 91 healthy controls or subjects with bipolar disease, Grunhage and coworkers
(2000) detected two rare missense substitutions and three silent mutations in the whole
coding region of DAT. Altered transport properties associated with some of the coding
variants of DAT suggest that individuals with these DAT variants experience functional
changes in the DA system (Lin and UhI2003).
-Above section taken/rom textbook review; Jayanthi et aI, 2007

1.3

Oligomerization of monoamine transporters

1.3.1. Monoamine Transporters are Oligomeric Structures
It has been hypothesized that monoaminergic transporters exist in the plasma membrane

of living cells in oligomeric form. Early studies showed that proteins that transverse
membranes appear to have structures of higher order in which the units are arranged
asymmetrically across the membrane and the axis of symmetry perpendicular to the
membrane plane.

This structure allows for the transporter to efficiently transport

nutrients across the cell membrane in a favorable manner (Klingenberg 1981; Veenhoff,
Heuberger et al. 2002). Other early evidence using radiation inactivation ofDAT showed
that ligand binding sites appeared to be formed to accept ligands of larger molecular
weight than the predicted amino acid sequence deduced size. For example, the apparent
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target binding site size for "the cocaine binding site" as measured with the cocaine
analogue 2 beta-[3H]carbomethoxy-3 beta-( 4-fluorophenyl)tropane was approximately
140 kDa. Also binding sites of GBR-12935 and mazindol (a OAT inhibitor and a OAT
substrate, respectively) after radiation inactivation were predicted to be larger than the
aforementioned 70 kOa (Berger, Farrell et al. 1994). A later study by Ramamoorthy, et al
using gel filtration chromatography showed that filtration fractions at higher molecular
weights (::::::360 kOa) bound the SERT antagonist and SSRI, paroxetine, while this binding
was not found at the expected 70 kOa, the molecular weight of monomer SERT. This
suggests that SERT must exist as a higher order oligomer to bind drugs such as
paroxetine (Ramamoorthy, Leibach et al. 1993).

Further studies used heterologous

expression of linear concatenates to help determine the quarternary structure of SERT.
Up to four copies of SERT concatenates showed discernible uptake for the monomer,
dimer, and tetramer but not the trimer. Interestingly, equivalent Km binding for cocaine
with all four forms of SERT were shown including the non-functional trimer (Chang,
Starnes et al. 1998). This data points to the possibility that while oligomerization is
necessary for 5-HT uptake it is not necessary for inhibitor binding. Also, treatment of
SERT

expressed

in

HEK-293

cells

with

sulfhydryl

oxidizing

agents

and

homobifunctional cross-liner dimethylsuberimidate (DMS) created SERT complexes of
130-180 kOa and 220-270 kDa, respectively, helping to create more evidence for the
oligomerization of SERT (Hastrup, Karlin et al. 2001). These studies were followed by
co-immunoprecipitation

data

using

inactivation

of SERT

proteins

with

(2-

aminoethyl)methanethiosulfonate (MTSEA)-biotin which has been shown to modify
external cysteine sulfhydryl groups.

These studies revealed that SERT could be
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expressed in higher oligomeric complexes such as tetramers (Kilic and Rudnick 2000).
Another co-immunoprecipitation study observing the oligomerization of DAT used HAand 6-His-tagged wild-type and dominant-negatively formed DAT.

Mutant DAT

composed of the mutation of important sites within DAT, (i.e. Y335A and D79G, both of
which are thought to be necessary for the function of the transporter) resulted in normal
trafficking of SERT while decreasing the uptake of 5-HT by SERT. Truncated mutants
at the C-terminal resulted in further impairment of the normal processing of 5-HT uptake
with respect to oligomerization. Another step forward in understanding the molecular
composition of monoamines is raised from the introduction of Fluorescence Resonance
Energy Transfer (FRET).

FRET imaging describes an energy transfer mechanism

between two chromophores. FRET has been used previously to examine oligomerization
of membrane proteins, including G protein-coupled receptors (Overton and Blumer 2000)
and ion channels (Riven, Kalmanzon et al. 2003).

FRET studies have revealed that

monoamine transporters are most likely complexed in the endoplasmic reticulum (ER)
during protein synthesis and that these homo- or hetero-oligomeric complexes, expressed
on the plasma membrane of immortalized dopaminergic cell line IRB3AN27 could be
internalized by phorbol esters and amphetamine (Sorkina, Doolen et al. 2003).

In

addition cysteine cross-linking studies have been performed to observe the quaternary
structure of DAT revealing domains within the transporter that may contain specific for
sites for oligomerization (Hastrup, Karlin et al. 2001; Norgaard-Nielsen, Norregaard et al.
2002). Also, studies using dominant negative forms of transporters have been performed
to help support the possibility of monoamine transporter oligomerization. Alternative
splice forms of rNET were created by alternative reading frame transcription and resulted
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in two splice forms of rat Net (rNET): rNETa and rNETb. rNETa resembles human NET
(hNET) whereas rNETb (the alternative splice form) has an alternate C-terminus from
rNETa and has no uptake ability.

However when co-expressed with rNETa, rNETb

decreased functional expression of the wild-type NET. Also when co-expressed with
other members of the NSS-symporter family: rat gamma-aminobutyric acid transporter
(rGATl), a rat serotonin transporter (rSERT), and a rat dopamine transporter (rDAT)
creating chimera transporters, functional expression and neurotransmitter uptake was also
decreased, however this was not found in glutamate/aspartate transporter also though to
form oligomers (Kitayama, Ikeda et al. 1999).

1.3.2 Possible Sites for Monoamine Transporter Oligomerization
It has been hypothesized that there are certain structural motifs within the
monoamine transporters that allow for possible transporter oligomerization. These motifs
vary in their consistency and their presence within the NSS-family.
The GxxxG Motif in TM6

The G(V/I)xxG(V/I) xx(AlT) or GxxxG motif originally identified in glycophorin
A, a protein found in red-blood cells (Lemmon, Treutlein et al. 1994), has been identified
in TM6 of DAT and is mostly conserved in other amino acid sequence in other NSSfamily members such as OAT, NET, SERT, and GAT-I. The second glycine (0) of the
GxxxG motif is conserved in all NSS-family members and is indispensible for
oligomerization.

It is possible that since this motif (a.a. 323-327) contains an

extracellular portion that is possibly reactive to disulfide crosslinking, there is a possible
opportunity of TM6-TM6 oligomerization of two DAT transporters. Mutation of the
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G327 to valine (G327V) disrupts proper plasma membrane trafficking of OAT and
therefore appears to be an important residue in normal SERT activity (Hastrup, Karlin et
al. 200 1). It has been reported that thiol retention within the ER is the mechanism behind
whether or not proteins are permitted to be exported from the ER.

In other words,

monitoring the redox state of cysteine residues of proteins being processed in the ER is
one gatekeeping step to creating properly folded and glycosylated proteins. Therefore it
can be extrapolated that mutation of various sites within monoamine transporters could
be targeted by the thiol retention system and subsequently never allowed to leave the ER,
and therefore never expressed on the plasma membrane. It is also possible that improper
oligomerization may be a cause for the alarm of the thiol retention system (Reddy and
Corley 1998). Therefore proper folding and oligomerization may be necessary for the
export of OAT and other similar transporters, such as SERT and NET, from the ER.
Transmembrane Domain 4 of DAT

Another symmetrical interface exists in TM4 of OAT. Cysteine depletion was
conducted by site-directed mutagenesis and only cysteines in TM4 (Cys243) and TM6
(Cys306) were left unmutated. Cysteine cross-linking experiments were then performed
and bands corresponding to dimer, trimers, and tetramers were expressed in SDS-P AGE
gel electrophoresis, much like in wild-type transporters without cysteine depletion. This
indicated that there are possible oligomerization sites between TM-4 and TM-6 in OAT.
This would allow OAT to oligomerize in a "dimer of dimers" form. While theoretically
possible, it is unfeasible to believe that OAT would exist in a larger quaternary structure
than a tetramer, most likely because the size of the protein would be too large for export
from the ER (Hastrup, Sen et al. 2003). It is also possible that because N- and C-termini
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of DAT and other family transporters interact with other proteins, it is possible that this
could limit the extended oligomerization array as well.
The Leucine Heptad Repeat in TM2 is involved in the oligomerization of monoamine
transporters

The leucine heptad motif, or the "leucine zipper", appears in many different
proteins and is thought to be a source of protein oligomerization. The leucine heptad
repeat appears in these different proteins with the generic formula:

LxxxxxxLxxxxxxLxxxxxxL

Where "L" stands for Leucine and "x" stands for any of six random residues that are
usually hydrophobic in nature (McCormack, Tanouya et al. 1991). This leucine heptad
repeat was first characterized in soluble transcription factors (Garcia, Nakai et al. 1997).
It was found later that four tandem leucine heptad repeats were responsible for the

dimerization of phospholamban, a modulator of the Ca2+ pump in cardiomyoctes (Sahinroth, Lawrence et al. 1994; Loland, Norregaard et al. 2002). It was later proposed by
Gurezka et aI, that leucine heptad repeats found in transmembrane region domains were
responsible for the oligomerization of plasma membrane proteins, and mutation of these
leucine sites to alanines disrupted oligomerization (Gurezka, Laage et al. 1999). More
recently the leucine zipper motif has been found to regulate oligomerization AKAP-LbC,
a member of the A-kinase anchoring protein (AKAPs) family, which functions as a
cAMP-dependent protein kinase (PKA)-targeting protein as well as a guanine nucleotide
exchange factor (GEF) for RhoA (Baisamy, lurisch et al. 2005). Therefore, the nature of
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the leucine amIno residue side chain may be important for causIng or stabilizing
oligomerization of transmembrane regions.
Leucine placement in the leucine heptad repeat allows the possibility of
interaction with other transmembrane domains in the protein (McCormack, Tanouya et
al. 1991). The six hydrophobic amino acid residues that are placed in between the
individualleucines allow for the formation of a hydrophobic pocket. Leucine side chains
(which are relatively long and hydrophobic) can then insert themselves into the
hydrophobic pocket of an adjacent identical transmembrane region creating a "zipper..
like" motif (Macara and Cantley 1981). Alanine mutation of leucines would eliminate
the side chain interaction with adjacent transmembrane regions therefore possibly
disrupting the "zippering" of transmembrane domain regions.

Since it appears that

oligomerization is necessary for monoamine transporters to be expressed on the plasma
membrane surface, the intact leucine zipper may provide an important role in achieving
this expression.
It appears that both DAT (Zhou, Merianos et al. 2001) and GAT-l (Burant and
Bell 1992; Fafoumoux, Noel et al. 1994) have been found to have leucine zipper repeats
within the transmembrane region 2 (TM2) and upon disruption of the zipper by alanine
mutation, uptake of DA and GABA is completely obliterated and extinguishes
oligomerization of these proteins. While SERT has not been studied there does appear to
be an imperfect leucine zipper located within TM2 as well. However several problems
arise to this being a strong possibility for an oligomerization site. 1) It is buried within a
transmembrane domain region and it has been thought that there is limited association of
polyleucine segments in the lipid bi-Iayer (Zhou, Cocco et al. 2000). 2) It has been

38

reported that leucine heptad repeats in ion channels, such as L-type calcium channels, are
more involved in gating than in oligomerization (McCormack, Tanouya et al. 1991).
Therefore, the role of the leucine heptad repeat in NSS-family transporters while
conserved needs more study.
The COOH- and NH2- terminus ofSERT may contain possible oligomerization sites

FRET microscopy has been used to study the C- and N- termini of monoamine
transporters.

The N- and C- terminal of SERT when tagged with two different

fluorophores of different wavelengths (CFP and YFP) can create a FRET signal, a signal
that is only possible if the two fluorophores are in the correct orientation and distance,
both of which are not left to chance (Just, Sitte et al. 2003). It has been shown through
FRET donor bleaching that oligomerization sites possibly exist in both TMI/TM2 and
TMII/TM12, the N- and C- termini respectively (Just, Sitte et al. 2003). Also another

GxxxG motif is found in TM12 of SERT, but is not found in other NSS-family members.
However because of the interaction of other proteins with these termini on the
transporters, the ability of these sites to undergo oligomerization is not understood and
warrant further investigation.

1.4

Hypothesis and Overview
The major hypothesis put forward in the dissertation is that oligomerization of

SERT can be regulated through phosphorylation by
phosphatases.

c~llular

protein kinases and

As already discussed in this chapter both oligomerization and

phosphorylation are important processes underlying monoamine transporter function, and
trafficking-dependent and -independent regulation. . The ability to understand this
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information and understand their interaction may lead to potential therapeutic agents that
can help treat the aforementioned disorders.
In Chapter 3.1 we hypothesized that activation of protein kinases such as PKG,
p38 MAPK, and PKC regulate SERT oligomerization. We tested this hypothesis using
various molecular techniques aimed at understanding whether these kinases had effects
on the status of SERT oligomerization. Results revealed that kinases including PKG and
p38 MAPK, that have been found to stimulate SERT-mediated 5-HT uptake, decrease
SERT oligomerization, and PKC, which has been shown to down-regulate SERT
function in concert with trafficking -dependent and -independent plasma membrane
expression of SERT, caused an increase in SERT oligomerization.
In Chapter 3.2, we then explored whether SERT phosphorylation is required for
regulation of SERT oligomerization. To study this we used site-directed mutagenesis to
direct point mutations at Thr276, the site we discovered was the only site in SERT for
PKG-dependent phosphorylation. Studies showed that mutation of Thr276 to aspartic
acid (T276D) created an increase in SERT uptake compared to controls and a decrease in
SERT oligomerization while this was not observed for the alanine mutation of Thr276
(T276A).
Lastly, Chapter 3.3 we studied whether human mutant polymorphisms within
SERT, that have been found in patients with various disorders, influences SERT
oligomerization. Also, in this section we studied the effect of the drug of abuse, cocaine,
on SERT oligomerization and the importance of SERT oligomerization for protein
synthesis and ER exportation.
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Chapter II.

Materials and Methods
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Materials

8-Br-cGMP was from Sigma (St. Louis, MO).

eH]5-HT (5-hydroxy-[3H]tryptamine

trifluoroacetate), ECL reagent, and ECL enhanced film were obtained from Amersham
Biosciences (Piscatway, NJ). All cell culture media and other reagents were purchased
from Invitrogen (Carlsbad, CA) HRP-conjugated secondary antibodies were obtained
from Jackson ImmunoResearch Laboratories (West Grove, PA) Anti-calnexin was from
Stressgen, (Victoria, Canada). The QuickChange site-directed mutagenesis kit was from
Stratagene (La Jolla, CA).

Rp-8-pcPT-cGMPs and KT5720 were from BIOMOL

(Plymouth Meeting, PA). KT5823 was from Fisher (Waltham, MA). Ni-NTA Superflow
Nickel-Column Beads were from Qiagen (Valencia, CA).

~-PMA

was from Alexis

(London, UK), PD 169316 was from Calbiochem (San Diego, CA). All other reagents
were of the highest grade possible from standard sources.

Cell-Culture

HEK-293 were maintained in Dulbecco's Modified Eagles Medium containing 10%
Hyclone fetal bovine serum, 1% penicillin 10,000 units/mL, 1% streptomycin 10,000
J.lg/mL; IX low glucose, L-glutamine, and 110 mg/L sodium pyruvate, pyridoxine
hydrochloride at 37°C in 5.0% C02/95% air. Cells were passaged every 48 hours in T25
flasks when reaching 80% confluency.

Transfection and Transient Expression

HEK-293 cells were plated at 100,000 cells/well on 1% Poly-D-Lysine treated 24-well
tissue culture plates a day before transfection for 5-HT uptake and 200,000 cells/well on
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12-well tissue culture plates a day before transfection for co-immunoprecipitation and
western blotting. Cells were transfected with hSERT plasm ids, the empty vector pcDNA3,
and/or other experimental DNAs (as indicated in figures), up to O.8Jlg total, using Lipofectamine
(Invitrogen) transfection reagent according to the manufacturer's protocols with Optimem cell
culture media antibiotic-free. Where indicated, cells were treated with different modulators as
described after 48h of transfection.

Site-Directed Mutagenesis

Threonine and Serine residues in hSERT intracellular domains were mutated to alanine or
aspartic acid residues using the QuikChange site-directed mutagenesis kit (Stratagene).
XhoIlAgeI or XbaI/AgeI fragments containing the mutated site(s) were then ligated into
correspondingly cut wild-type hSERT. Mutations were then confirmed by nucleic acid
sequencing the DNAs on both strands at the Medical University of South Carolina DNA
Sequence Facility.

SERT Activity (5-HT Uptake Assal:)

For uptake studies, SERT-transfected HEK-293 cells were plated at 100,000 cells/well in
12-well plates, 3 days before experiments.

At assay, the medium was removed by

aspiration, and cells were washed with 1 ml of Krebs-Ringer's-HEPES (KRH) medium
containing (in mM): 130 NaCI, 1.3 KCL, 2.2 CaCl2, 1.2 MgS0 4 , 1.2 KH2P04, 10
HEPES, pH 7.4. The wash was then removed and the cells were reincubated in KRH
containing 1.8 gmlL glucose,

100~M

pargyline, and

100~M

ascorbic acid ("assay

buffer") for 5 minutes. PKG activator 8-Br-cGMP (Sigma) at 2.5mM was then added to
half the cells while "assay buffer" was used as a vehicle control. Cells were then placed
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in an incubator at 37°C in 5.0% C02/95% air for 30 minutes. Plates were then removed
from the incubator and 5-HT transport assays (15 min at room temperature, added to each
well at 10 second intervals) were initiated by the addition of eH]5-HT (5-hydroxy-eH]
tryptamine trifluoroacetate --100 Ci/mmol. Assays were then terminated by three rapid
washes of 37°C KRH containing 1JlM imipramine at 10 second intervals. Imipramine, as
a SERT antagonist, was used to block 5-HT uptake by SERT. Cells were then lysed in
National Diagnostics Ecoscint cocktail and accumulated radioactivity directly quantified
in a mircroplate liquid scintillation counter. During inhibitor studies, PKG inhibitor Rp8-pcPT-cGMPs was added 30 minutes prior to incubation with 8-Br-cGMP. Activation
of PKC by

~-PMA

was initiated by pre-incubating HEK-293 cells with 10 JlM B-PMA

for 30 minutes at 37°C.

Inhibition of PKC by Staurosporine was initiated by pre-

incubating HEK-293 cells with 10 JlM Staurosporine for 30 minutes at 37°C followed by
above directions for 5-HT uptake.

Nickel-Column Chromatography

For Nickel-Column studies, HEK-293 cells (transfected with HIS-tagged and HA-tagged
SERT) were seeded on poly-D-Iysine-coated 12-well plates at 2.5

x

105 cells/well. After

48 h, cells were washed one time with Kreb's-Ringer-Hepes Buffer (described above)
and then incubated with 500 JlI lysis buffer (IX PBS, IX Triton-X, and protease
inhibitors;

1Jlg/ml

aprotinin,

I Jlg/ml

leupeptin,

1JlM

pepstatin,

and

250JlM

phenylmethylsulfonyl fluoride for I hr at 4°C. Samples were then collected, syringed up
and down 4 times, and spun at 25,000 x g for 30 min at 4°C and supernatant was removed
and collected for total fraction. Supernatant was then incubated with 100 JlI Ni-NTA
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agarose coated beads (Qiagen) and rotated at RT for 1 hr. Slurry was then spun at 10,000
x g for 10 minutes and the unbound fraction was collected. Remaining beads were then
washed three times with lysis buffer with spins at 10,000 x g for 5 minutes between
washes at 4°C. After last wash beads were eluted with 50 flilysis buffer + 10mM EOTA
and rotated end-over-end for 20 min at RT. Beads were then spun at 10,000 x g for 10
min. at 4°C and supernatant removed for bound fraction. 10 III of Laemmli sample buffer
(62.5mM Tris-HCI, pH 6.8, 20% glycerol, 2% SOS, 5% ~-mercaptoethanol, and 0.01 %
bromphenol blue) is added to each collected sample, incubated for 30 min at RT, and then
resolved by SDS-PAGE (100/0), probed with specific antibodies as indicated in the figure
and legends and visualized by chemiluminescence (ECL plus).

Immunoblotting

SERT immunoprecipitations and immunoblotting were perfonned on transfected HEK293 cells. Protein samples were subjected to 4-15% linear gradient SOS-PAGE, blotted
to polyvinylidene difluoride membrane, and probed with specific antibodies as indicated
in figures and legends. Immunoreactive bands were visualized by chemiluminescence
(ECL reagent). Multiple exposures of blots were obtained to ensure the development
within the linear range of the film. Band intensities were quantified using NIH Image
(version 1.6).

Statistics

Unless indicated otherwise, experiments were conducted in triplicate and the mean values
± S.E.M. from three independent experiments are compounded to form statistical

45

conclusions. Student's t test was performed for paired observations. A value of P<O.05
is considered statistically significant.
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Chapter III. RESUL TS
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3.1

Aim 1: Does Protein Kinase Activation Regulate SERT Oligomerization?
Protein kinases that stimulate SERT activity in HEK-293 cells decrease SERT

oligomerization: Understanding that activation ofPKG by cGMP analogs increased 5-HT

uptake we sought to see if activation of PKG had an effect on SERT oligomerization.
There have been no studies preferred on SERT that show if phosphorylation has an effect
on structure of the transporter. Therefore we chose Ni 2+ affinity chromatography to
assess SERT oligomerization after activation ofPKG. We chose to use HEK-293 cells
because they appeared to contain less non-significant proteins that were recognized by
our HA-antibody than eHG cells as was used in our previous work (data not shown).
We first looked at the specificity of our antibodies to detect Influenza derived
HA-antibody and HIS-antibody after Ni2+ chromatography. Plasmid expression vectors
were created containing SERT with either a 6-His antibody epitope tag (HIS: HHHHHH)
or a small portion of the Influenze A Virus Hemagglutin coat protein (HA:
YPYDVPKYA) directly after the ATG start codon ofSERT both of which are easily
recognizable by HIS and HA antibodies, respectively. We therefore transfected HEK293 cells with one of five conditions: (in order Lanes 1-5), Non-transfected, wild-type
SERT with no antibody tag (WT-SERT-NT), HIS-wild-type SERT (HIS-WT-SERT),
HA-wild-type SERT (HA-WT-SERT), and co-transfection ofHIS-WT-SERT + HA-WTSERT. Fig 1-1 shows that probing the total fraction for HA-antibody revealed presence
ofHA-tagged SERT in both the HA-WT-SERT and the co-transfected HIS-WT-SERT +
HA-WT-SERT condition but not in remaining lanes. Probing for HA-antibody in the
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Fig. 1-1). HA- and His- Antibody specificity in HEK-293 cells. HEK-293 cells
were transfected is plasmid expression vectors as indicated. After 48-hrs posttransfection cells were exposed to Ni2+ affinity chromatography as described
under "Materials and Methods". A representative immunoblot of three separate
experiments showed that Ni 2+ column beads were specific for HIS-tagged
SERT proteins. (HIS-WT-SERT) HA-tagged WT SERT (HA-WT-SERT) is
present in only the condition where it was co-transfected with HIS-WT-SERT
conferring sensitivity and accuracy of the Ni 2+ affinity chromatography
technique.
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bound fraction only revealed HA-SERT in the co-transfected lane, showing that the Ni 2+
column affinity chromatography was sufficient for detecting the presence of HA-tagged
SERT after co-ip and is a reliable measure for studying oligomerization of SERT. Lastly,
reprobing of the membrane with 6-His antibody revealed HIS-tagged proteins in both the
HIS-WT-SERT and the co-transfected lanes. Therefore from this data we can conclude
that our antibodies and our techniques are specific.
Our first task was to look at the stimulatory kinase, PKG and its effect on SERT
oligomerization. HEK-293 cells were seeded as discussed in "t\1aterials and Methods"
and 24 hours later, transfected with His6-SERT-pcDNA3 + HA-SERT-pcDNA3 in
conjunction with either PKG or Mutant Protein Kinase G (MutPKG). MutPKG has a
mutation at the ATP binding site that does not allow it to bind SERT. 48-hours posttransfection cells were treated with 8-Br-cGMP for 10 minutes at 37°C and then lysed
and assessed for [3 H]5-HT uptake and oligomerization. Fig. 1-2 shows that cells
transfected with PKG and treated with cGMP experienced an increase in SERT uptake
compared to MutPKG transfected HEK-293 cells as we had previously seen in our
synaptosomal and CHO-1 cell studies. Interestingly, Fig. 1-3 shows that activation of
PKG by 8-Br-cGMP, while having an effect on increasing SERT uptake, appears to
decrease SERT oligomerization as observed in the Ni2+ co-immunoprecipitation (Lane 2)
compared to no significant change in oligomerization as seen in the MutPKG control
(Lane 4).
Since we found that PKG stimulation by 8-Br-cGMP increased uptake and
decreased SERT oligomerization we looked at p38 MAPK, another kinase that has also
been found to stimulate 5-HT uptake by SERT. Therefore, we co-transfected MKK3, the
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Fig. 1-2) Effect of PKG phosphorylation on SERT 5-HT uptake. HEK-293 cells
were transfected with expression plasmids as indicated. After 48-hrs. posttransfection, cells were washed once with KRH Buffer and pre-treated with 8-BrcGMP (250 JlM) for 10 minutes at 37°C. Nickel-affinity chromatography was
performed to study SERT oligomerization as "Materials and Methods". (AJ SERT
Immunoblot. HEK-293 cells transfected with PKG showed a decrease in
oligomerization in the bound fraction compared to little change to cells
transfected with Mutant PKG (*p<O.05). (BJ Quantitative analysis of SERT
band densities. SERT band proteins were quantified with NIH Image J, and the
densities of SERT from three separate experiments are presented as mean ±
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Fig. 1-3) Effect of PKG phosphorylation on SERT oligomerization. HEK-293
cells were transfected with expression plasmids as indicated. After 48-hrs. posttransfection, cells were washed once with KRH Buffer and pre-treated with 8-BrcGMP (250 ~M) for 10 minutes at 37°C. Nickel-affinity chromatography was
performed to study SERT oligomerization as "Materials and Methods". (A) SERT
Immunoblot. HEK-293 cells transfected with PKG showed a decrease in
oligomerization in the bound fraction compared to little change to cells
transfected with Mutant PKG (*p <O.05). (B) Quantitative analysis ofSERT band
densities. SERT band proteins were quantified with NIH Image J, and the
densities of SERT from three separate experiments are presented as mean ±
S.E.M.
52

constitutively active form of MAP Kinase Kinase (MEK), the upstream kinase from p38
MAPK, with HA-tagged wild-type SERT into HEK-293 cells for 48 hrs and assessed the
cells for eH]5-HT uptake (Fig. 1-4). It was found that co-transfection with MKK3
caused SERT activity to increase by about 50% compared to wild-type SERT cotransfected with pcDNA3. However when we incubated transfected cells with the p38
MAPK inhibitor PD169316, it blocked the ability ofMKK3 to increase SERT uptake of
5-HT (Fig 1-4). Thus stimulation ofp38 MAPK appears to increase SERT activity.
Next, we sought to see ifp38 MAPK had a similar effect as PKG on decreasing SERT
oligomerization. Once again we transfected HEK-293 cells with the same conditions as
in Figure 1-4 and performed Ni 2+ affinity chromatography with the celllysates. Figure 15 shows that as with activation ofPKG, activation ofp38 MAPK by MKK3 caused a
decrease in SERT oligomerization that could be blocked by pre-incubation with the p38
MAPK inhibitor PD169316. It was also seen that pre-incubation of the control condition
(HA-WT-SERT + HIS-WT-SERT + pcDNA3) with PD169316 caused an increase in
SERT oligomerization greater than the basal level of oligomerization. Since it has been
proposed that p38 MAPK basally phosphorylates SERT (Samuvel, Jayanthi et al. 2005),
it is possible that basal phosphorylation maintains a certain endogenous state of
oligomerization.
Conversely, PKC decreases SERT uptake while increasing SERT oligomerization:
It has been previously shown that activation ofPKC with phorbol esters (fJ-PMA) or

inhibition of protein phosphatases PPI/PP2A with okadaic acid decreases SERT uptake
(Ramamoorthy, Giovanetti et al. 1998). Therefore we decided to see ifHA- and HIStagged SERT proteins performed the same level of 5-HT uptake as untagged SERT when
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Fig. 1-4) Effect of MKK3 and PD169316 (a p38 MAPK inhibitor) on 5-HT
uptake by SERT HEK-293 cells were transfected with expression plasmids as
indicated. After 48-hrs post-transfection, 5-HT uptake was assessed as described
under "Materials and Methods". HEK-293 cells expressing MKK3 experience
increased 5-HT uptake as compared to cells pre-treated with 10 JlM PD169316
for 30 minutes at 37°C (*p<O.05). PD169316 has no effect itself in governing 5HTuptake.
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Fig. 1-5) Effect ofp38 MAPKphosphorylation on SERT oligomerization. HEK293 cells were transfected with expression plasmids as indicated. After 48-hrs.
post-transfection cells lysates were exposed to nickel-affinity chromatography
beads and assessed SERT oligomerization as described in "Materials and
Methods".
(A) SERT Immunoblot.
SERT oligomerization decreased in
experiments where MKK3 transfection was present and could be blocked by preincubation of 10 JlM PD169316 for 30 min at 37°C (*p<O.05). Interestingly,
PD169316 also had an effect on increasing SERT oligomerization (*p <O.05).
(B) Quantitative analysis of SERT band densities. Bound extract from SERT
were quantified using NIH ImageJ. The densities of the SERT band from three
separate experiments are presented as mean ± S.E.M. Student's t test was used to
anal yze data.
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exposed to phorbol ester treatment. Figure 1-6 shows that either HA -WT -SERT or HISWT-SERT, when co-incubated with

~-PMA,

showed a decrease in SERT uptake of

eH]5-HT. This effect could be blocked by the PKC inhibitor staurosporine.
Staurosporine itself appeared to have no effect on 5-HT uptake by SERT (Fig. 1-6).
Seeing a decrease in SERT activity we were interested to see if there was an effect on
oligomerization of SERT by activation of PKC. Surprisingly, Figure 1-7 shows that
activation ofPKC by

~-PMA

creates an increase in SERT oligomerization. This effect

could be blocked by pre-incubation of the PKC inhibitor staurosporine.
There are three possible methods to rapidly regulating transport of 5-HT
molecules across the plasma membrane: (1) regulation of the open probability of the
transporter, (2) regulation of the permeability of the transporter. and (3) regulation of the
number of transporters available at the plasma membrane surface for 5-HT translocation.
Our previous work has shown that PKG regulates changes in the rate of 5-HT
translocation by increasing the Vmax of the transporter upon phosphorylation while not
changing affinity or Km of 5-HT for SERT (Ramamoorthy, Samuvel et al. 2007). Other
work has shown that activation ofPKC increases SERT endocytosis and decrease SERT
uptake of 5-HT (Ramamoorthy, Giovanetti et al. 1998). Therefore, it is possible that
different kinases that act on different phosphorylation sites throughout SERT (e.g. PKG

-7 T276) affect oligomerization that causes changes in one or more of the above three
possibilities. For example it is possible that phosphorylation of SERT by PKC causes
previously unexposed oligomerization sites to be exposed and cause and increase in
oligomerization. This change in oligomerization may be a signal for the recruitment of
endocytotic machinery involved in the internalization of SERT from the plasma
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membrane. Conversely, activation ofPKG may decrease SERT oligomerization and
subsequently allow the recycling rate of the transporter (the rate at which the transporter
resets to accept more ligand) to increase causing a greater influx of 5-HT than if SERT
had not been phosphorylated at all. More work understanding SERT binding protein
interactions, kinetics, and trafficking will aid in understanding this phenomenon.
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Fig. 1-6) Effect of{J-PMA and staurosporine on SERT uptake in HEK-293 cells.
(AJ HEK-293 cells were transfected with HA-WT SERT as indicated. After 48hrs post-transfection, cells were washed once with KRH buffer and treated with
~-PMA for 30 min at 37°C. 15 minutes into ~-PMA treatment, cells were either
given staurosporine (a PKC inhibitor) or vehicle assay buffer. HEK-cells were
the assayed for 5-HT uptake as described under "Materials and Methods". (BJ
HEK-293 cells were treated the same as in (AJ but HIS-WT SERT was
transfected instead of HA-WT SERT and the same protocol was used as in (AJ.
Both studies revealed that treatment with ~-PMA for 30 minutes decreased SERT
uptake of 5-HT, (*p<0.03). However pre-incubation of staurosporine, blocked
~-PMA's effect of decreasing uptake of 5-HT by SERT. Staurosporine itself had
no effect on SERT uptake.
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Fig. 1-7) Effect of fJ-P MA and subsequent activation of P KC on SERT
oligomerization. (AJ SERT Immunoblot. HEK-293 cells were pre-treated with or
without ~-PMA for 30 min at 37°C. At 15 minutes post-~-PMA incubation cells
were treated with either staurosporine or assay buffer for the remaining 15
minutes.
Cells were then exposed to Ni-NTA Superflow affinity
chromatography as described under "Materials and Methods". Results show (AJ
incubation with ~-PMA increase SERT oligomerization (*p<0.03) while this
effect can be blocked with co-incubation of staurosporine. Staurosporine itself
had no effect on SERT oligomerization. (BJ Quantitative analysis ofSERT band
densities. Ni 2+ affinity chromatography of SERT proteins was quantified by NIH
ImageJ, and the densities of SERT bands from three independent and separate
experiments are represented as mean ± S .E.M. * indicates significant differences
compared to vehicle (*p<O. 05) by student's t test.
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3.2
Aim 2: Is SERT Phosphorylation Required For Regulation of SERT
Oligomerization?
Mutations at the PKG phosphorylation site, Thr276, mimic activation ofPKG by
8-Br-cGMP: We have previously shown that PKG phosphorylates SERT at Thr276
(Ramamoorthy, Samuvel et al. 2007) and that this effect is trafficking-independent.
Therefore we were curious to see if mutations at this site had an effect on SERT
oligomerization. We used site-directed mutagenesis to generate alanine (T276A) and
aspartic acid (T276D) polymorphisms at Thr276. We have previously shown that T276A
blocks the effect of increasing SERT activity by cell permeable cGMP analogs and that
the T276D mutation mimics the cGMP effect alone and further stimulation by 8-BrcGMP is not possible (Ramamoorthy, Samuvel et al. 2007). Therefore we co-expressed
WT-SERT with varying concentrations of empty vector pcDNA3, T276A-SERT, or
T276D-SERT. Figure 2-1A shows that increasing amounts ofT276D co-transfected with
consistent amounts of wild-type SERT showed increased uptake compared to control
conditions (WT-SERT + pcDNA3). This effect was not present in co-transfections of
WT-SERT + T276A (Fig 2-1B). To make sure that our HIS- and HA-tagged SERT
worked in the same fashion as untagged mutants we performed the same experiment
using HA- and His6-SERT. Figure 2-2A and 2-2B show that HIS- and HA-SERT
perform similar levels of uptake as untagged SERT, respectively.
Therefore understanding that SERT activity is increased by mutation to aspartic
acid, T276D, and is not altered when mutated to alanine T276A we used these mutations
as a tool to look at SERT oligomerization when SERT is in a mimicked state of
phosphorylation or when SERT cannot be phosphorylated by PKG, respectively. The
data in Figure 2-3 show that mutation to alanine or aspartic acid significantly decreased
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Fig. 2-1) Effect of co-transfection of SERT mutants with wild-type SERT in HEK293 cells. HEK-293 cells were transfected with expression plasmids as
indicated. After 48-hrs post-transfection, 5-HT uptake was assessed as described
under "Materials and Methods". (A) (*p<0.05) indicates significant differences
between wild-type SERT plus empty expression vector pcDNA3 and wild-type
SERT plus mutant T276D SERT. (B) This effect was not present in the
condition using T276A SERT in place of T276D SERT. Student's t test was
used for statistical analysis between conditions.
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differences between HIS-tagged wild-type SERT plus empty vector pcDNA3 and
HIS-tagged wild-type SERT plus HIS-tagged mutant T276D SERT. (B)
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wild-type SERT plus HA-tagged mutant T276D SERT.
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Fig. 2-3) Effect of site-directed mutagenesis SERT mutants at Thr276 results in
decreased SERT oligomerization. (A) SERT immunoblot. HEK-293 cells were
transfected with HIS-WT and one of three conditions (HA-WT, HA-T276A, and
HA-T276D) as shown. Cells were also transfected with pcDNA3 + HA-WT as a
negative control (last lane). Results show that co-transfection of HIS-WT SERT
+ HA-T276D results in a decrease in oligomerization some but not significant
change was seen in the condition HIS-WT SERT + HA-T276A. (B) Quantitative
analysis of SERT band densities. Ni 2+ affinity chromatography of SERT proteins
was quantified by NIH ImageJ, and the densities of SERT bands from three
independent and separate experiments are represented as mean ± S.E.M. *
indicates significant differences compared to vehicle (*p<O. 05) and (*p <O. 01) by
student's t test.

SERT oligomerization much as the data seen in Figure 1-3. It is important to note that
while co-transfection ofT276A SERT with WT-SERT caused no increase in SERT
uptake (Fig 2-1) it still appeared to cause a slightly significant decrease in SERT
oligomerization compared to wild-type control. To address the ability of the constructed
SERT mutants to form oligomers themselves, we transfected varying combinations of
HIS-WT-SERT, HA-WT-SERT, HIS-T276D-SERT, and HA-T276D-SERT as shown in
Figure 2-4. Oligomerization of SERT is decreased regardless of the tag of mutation (both
His6-T276D and HA-T276D SERT show decreased oligomerization at approximately the
same expression level (Fig. 2-4) ruling out any artifact that may have been being caused
by the antibody tag, and interestingly, SERT is still able to form an oligomer when both
mutant conditions are transfected together (HIS-T276D-SERT + HA-T276D-SERT).
This finding suggests that mutations that mimic phosphorylation of SERT by PKG
(T276D) also show the same pattern of decreased SERT oligomerization. Furthermore,
the ability ofHIS-T276D-SERT and HA-T276D-SERT to form an oligomer raises the
question as to the quaternary structure ofSERT. We have shown that p38 MAPK
activation phosphorylates SERT at T276 and another unknown putative phosphorylation
site (unpublished results). Therefore we looked to see if mutation at Thr276 to alanine
could block the decrease in oligomerization that was found when HEK-293 cells were cotransfected with wild-type SERT and the constitutively active upstream kinase ofp38
MAPK, MKK3. Figure 2-5 shows that while MKK3 does decrease SERT
oligomerization (as seen in Figure 2-5A) this effect is not blocked by co-transfection of
the inert T276A, leaving the possibility that other phosphorylation sites may be
responsible for basal phosphorylation ofSERT by p38 MAPK besides Thr276.
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monomers. (A) SERT Immunoblot. HEK-293 cells were transfected with
expression plasmids as shown. T276D constructs (HA- and HIS-) when cotransfected with the corresponding wild-type SERT both showed decreases in
SERT oligomerization. However, when both constructs were co-transfected
together (Lane D) a band was still present signifying that SERT is able to create
structures of higher order than monomers. (B) Quantitative analysis of SERT
band densities. Ni 2+ affinity chromatography of SERT proteins was quantified by
NIH ImageJ, and the densities of SERT bands from three independent and
separate experiments are represented as mean ± S .E.M. * indicates significant
differences compared to vehicle (*p< 0.05) by student's t test.
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MKK3. (A) SERT immunoblot. HEK-293 cells were transfected with expression
plasmids as shown. Lane A) HIS-WT + HA-WT + pcDNA3, Lane B) HIS-WT +
HA-WT + MKK3 , Lane C) HIS-WT + HA-T276A + pcDNA3, Lane D) HIS-WT
+ HA-T276A + MKK3. Co-transfection ofMKK3 with wild-type SERT showed
a decrease in SERT oligomerization as in Figure 5. Cooctransfection of MKK3
with HA-T276A (shown before not to provide a significant decrease in SERT
oligomerization) did not block or reverse the effect of MKK3 ,on SERT
oligomerization. (B) Quantitative analysis of SERT band densities. Ni2+ affinity
chromatography of SERT proteins was quantified by NIH ImageJ, and the
densities of SERT bands from three independent and separate experiments are
represented as mean ± S.E.M. * indicates significant differences compared to
vehicle (*p<O. 01) by student's t test.
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3.4

Aim 3: Do Human SERT Variants That are Resistant to PKG and p38

MAPK Regulation Affect SERT Oligomerization?
Human mutant polymorphisms at Is0425(V) and Gly56(A) also appear to affect
oligomerization in the same fashion as kinases that increase SERT activity (P KG and p38

MAPK): Previously, human mutations at I425V and G56A that have been found in
patients that suffer from obsessive-compulsive disorder, appear to increase SERT activity
with no further stimulation by PKG agonists. Therefore, we sought to distinguish if these
polymorphisms appeared to also have an effect on SERT oligomerization. In figure 3-1,
HEK-293 cells were transfected with expression plasmids as shown in the picture and
incubated with 8-Br-cGMP as described above. The control condition (HIS-WT-SERT +
HA-WT-SERT) is in agreement with our previous data with respect to 8-Br-cGMP, but
interestingly, co-incubation ofHIS-WT-SERT + HA-I425V-SERT revealed decreased
oligomerization on its own with no further decrease in oligomerization with 8-Br-cGMP
incubation. It has been shown that mutation ofT276 to alanine (T276A) blocks the
ability of I425V to increase SERT uptake of 5-HT (Zhang and Rudnick 2005), however
our data show that the double mutant (HA-I425V/T276A) co-transfected with HIS-WTSERT showed the same decrease in the single mutant condition in oligomerization with
or without PKG activation by 8-Br-cGMP.
G56A is another human polymorphism that has been associated with obsessivecompulsive disorder and increased 5-HT uptake by SERT. Therefore we performed the
experiments as in Figure 3-1 and assessed the oligomerization state of SERI. Much like
Fig. 3-1, incubation of the wild-type condition with 8-Br-cGMP caused a decrease in
SERT oligomerization (Fig. 3-2). Also, co-transfection ofHA-G56A-SERT with HIS-
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Fig. 3-1) Effect of human mutant polymorphism 1425 V on SERT oligomerization.
(A) SERT Immunoblot. HEK-293 cells were transfected with expression
plasmids as shown. Cells were washed once with KRH buffer and then preincubated with or without 8-Br-cGMP (250 JlM) for 10 minutes at 37°C. Cells
were then exposed to Ni 2+ affinity chromatography and assayed by SDS-PAGE.
As quantitated in (B) , treatment of wild-type SERT with cGMP resulted in a
decrease in SERT oligomerization as similar to Figure 1-3. Interestingly, cotransfection with I425V results in a similar decrease as wild-type SERT + cGMP
but no further decrease was seen when this condition was further exposed to 8Br-cGMP. Also co-transfection of HIS-WT-SERT + the double mutant HAI425V/T276A did not block the human polymorphisms ability to decrease SERT
uptake without cGMP, which also had no further effect (*p<O.05).
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Fig. 3-2) Effect of human mutant polymorphism G56A on SERT oligomerization.
(A) SERT Immunoblot.
HEK-293 cells were transfected with expression
plasmids as shown. Cells were washed once with KRH buffer and then preincubated with or without 8-Br-cGMP (250 ~M) for 10 minutes at 37°C. Cells
were then exposed to Ni 2+ affinity chromatography and assayed by SDS-PAGE.
As quantitated in (B), treatment of wild-type SERT \vith cGMP resulted in a
decrease in SERT oligomerization as similar to Figure 1-4. Interestingly, cotransfection with G56A results in a similar decrease as wild-type SERT + cGMP,
(*p<0.05). The double mutant HA-G56A1I425V SERT co-transfected with HISWT-SERT also showed a decrease in SERT oligomerization. Interestingly,
treatment of either condition with 8-Br-cGMP resulted in a further decrease in
SERT oligomerization (**p<0.03).
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WT -SERT caused a decrease in SERT oligomerization. However unlike experiments
with 1425V, Ni2+ affinity chromatography experiments with G56A revealed an additional
decrease in oligomerization when incubated with 8-Br-cGMP for 10 min at 37°C. The
double mutant (G56A1T276A) is similar to 1425V/T276A in that it does not block the
decrease in oligomerization either, but in fact shows a further decrease in oligomerization
when treated with 8-Br-cGMP (Fig. 3-2).

Proper oligomerization ofSERT is necessary for SERT exportationfrom the ER.
It has been proposed that monoamine transporter oligomerization is necessary for ER
exportation. Therefore, we wanted to confirm if indeed co-expression of varying SERT
proteins (HA-WT-SERT, HIS-WT-SERT) do indeed only form oligomers if cotransfected in HEK-293 cells. We transfected cells with the two variants together in the
same well (co-transfected) or in different wells and mixed the two together before
experimentation. The results in Figure 3-3 show that co-transfection ofHIS-WT-SERT +
HA-WT-SERT showed a band in the bound fraction while the condition in which HISWT-SERT and HA-WT-SERT were transfected separately and the mixed showed no
band in its corresponding lane. Therefore it is possible that since HA-epitope tags cannot
bind to Ni 2+ chromatography beads that SERT oligomers are only created by proper
folding, glycosylation, and complexing in the ER and the Golgi complex.

Effect of the drug of abuse, cocaine, on SERT oligomerization. Cocaine has been
shown to block not only SERT but other monoamine transporters as well such as DAT
and NET (Farde, Halldin et al. 1994; Miller, Yatin et al. 2001). Blocking SERT by
cocaine treatment causes a decrease in SERT's ability to perform 5-HT uptake.
Therefore., we chose a range of concentrations of cocaine that ranged from 0-50 JlM.
70

A
.
C
j:

A B
i

~

Totall

A = HA-WT'+ HIS-WT' (G~transileeted)
B HA-WT + HIS-WT f':mllxedt

=

B

I
Fig. 3-3) Oligomerization of SERT only occurs when protein is properly
packaged in the endoplasmic reticulum. (A) SERT Immunoblot. HEK-293 cells
were transfected with expression plasmids as shown. Lane A) HIS-WT-SERT +
HA-WT-SERT (co-transfected), Lane B) HIS-WT-SERT + HA-I425V

(transfected in separate wells and then lysates mixed). After 48-hrs posttransfection cells were lysed and exposed to Ni2+ affinity chromatography.
Immunoblotting revealed that co-transfection of HIS-WT-SERT with HA-WTSERT (Lane A) results in oligomerization of the SERT proteins. Lysates in Lane
B were mixed and show that no band is present in the bound fraction. (B) shows
graphical representation of immunoblot (A).
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HEK-293 cells were transfected with HIS-WT-SERT +

HA-Wl~ . . SERT

and 48 hrs pre-

incubated with the range of cocaine concentrations listed above for 30 minutes at 37°C
before assayed by Ni2+ affinity chromatography. Ni2+ Co-immunoprecipitation
experiments, in figure 3-4, revealed a response to cocaine treatment in a typical bellshaped curve with the highest and only significant finding at the 7.5 JlM cocaine
concentration (---50% increase in SERT oligomerization compared to no cocaine
treatment [0 JlM]). This result requires further study as this is the first time it has been
reported that, in addition to protein kinases affecting SERT oligomerization, drugs of
abuse affect SERT oligomerization. Therefore, oligomerization of SERT may have some
importance understanding the mechanism of function underlying cocaine abuse.
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Fig. 3-4) Cocaine appears to increase SERT oligomerization in HEK-293 cells.
(AJ SERT Immunoblot. HEK-293 cells were transfected with HIS-WT SERT +
HA-WT SERT expression plasmids. 48-hrs post-transfection cells were treated
with a varying range of cocaine concentrations [0-50 J.lM] for 30 min at 37°C and
exposed to Ni 2+ affinity chromatography. Results show that there was an
increase in SERT oligomerization at the 7.5 J.lM concentration of cocaine. (B)
Quantitative Analysis of SERT band densities. SERT bands were quantitated
using NIH ImageJ, and the densities of SERT bands from three independent
experiments are presented as mean ± S.E.M. (*p<O.05).
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Chapter IV. DISCUSSION
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In this study we have further studied the role of phosphorylation not only on
SERT uptake and surface expression but also on oligomerization of SERT in HEK-293
cells. The main conclusions from the studies reveal that SERT exists in HEK-293 as an
oligomer and can be affected and manipulated by cellular changes. The first piece of
evidence that supports this theory is that stimulation of various common cellular kinases
known to interact with SERT affect oligomerization as witnessed through Ni2+ affinity
chromatography. Second, we have provided evidence that mutation of the known PKG
phosphorylation site, Thr276, mimics PKG effects on SERT oligomerization. Third, we
have also shown that human mutant polymorphisms that are found in disease such as

,oeD and autism, respectively, appear to also affect oligomerization of SERT and that coexpression of human mutant polymorphisms with wild-type SERT are necessary for
oligomerization. Lastly, drugs of abuse such as cocaine appear to affect the topological
structure of SERT oligomerization.
First we found that activation of protein kinases (PKG and p38 MAPK) that
appear to have a stimulatory effect on SERT activity decrease SERT oligomerization.
Previous findings have indicated that stimulation of histamine (Launay, Bondoux et al.
1994), adenosine A3 receptors (Miller and Hoffman 1994), nitric oxide synthase (Zhu,
Hewlett et al. 2004), and activation of protein kinases with cell-permeable analogs
activate the PKG pathway and increase SERT activity and suggested that this stimulatory
effect occurs through a change in Vmax but not Km (Ramamoorthy, Samuvel et aI. 2007).
It is possible that phosphorylation of SERT causes an uncoupling of the aforementioned
methods of creating SERT oligomerization. The change in V max by PKG phosphorylation
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as mentioned above may be a direct result of the change in oligomerization state of the
transporter after phosphorylation. It is possible that lower quarternary structures of
SERT (i.e. the monomer) may translocate 5-HT more rapidly than higher homooligomeric structures. It may also be that during this time while SERT is "deoligomerized" it may have the opportunity to bind with known pre-synaptic proteins.
One of these proteins in particular is a neuronal SNARE (soluble N-ethylmaleimidesensitive factor-attachment protein receptor) protein syntaxin-IA (SynlA). SynlA is a
pre-synaptic protein that has been found to be important for vesicle docking in the CNS
and genetic knock-out of Syn 1A results in a decrease in the vesicle recycling pool and the
number of vesicles exocytosed during brief action potential trains (Ryan, Li et al. 1996),
The SynlA protein has been shown to associate with SERT at the N-terminal (Haase
2001; J. Haase 2001; Sung, Apparsundaram et al. 2003) and in lIpid raft fractions in
HEK-293 cells and rat brain homogenate (Muller, Wiborg et al. 2006). Experiments
performed have shown that cleavage ofSynlA with botulinum toxin Cl decreases 5-HT
function by decreasing transport capacity without changing the affinity of 5-HT for SERT
(Quick 2002). Also, interaction of SynlA with SERT has shown to be decreased by
activation ofPKC (Haase 2001; 1. Haase 2001; Quick 2002) and inhibition ofp38 MAPK
with the inhibitor PD169316 (Samuvel, Jayanthi et al. 2005). It is therefore possible that
activation of the PKG pathway causes directly or indirectly a decrease in SERT
oligomerization, greater SynlA-SERT association, and an increase in 5-HT uptake
activity. Since SynlA has been found to bind to the N-terminal ofSERT and appears to
be the mechanism of association for these proteins, it is possible that the "deoligomerization" of SERT exposes sites within the N-terminal that make SynlA more
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readily able to bind SERT. Since disruption of SynlA-SERT binding decreases SERT
5-HT uptake it is feasible to predict that a phosphorylation path,vay that decreases
oligomerization actually increases SERT activity by increasing SynlA-SERT interaction
or a similar protein necessary for vesicle fusion. Further studies need to be performed
looking at co-immunoprecipitation changes in association of SERT-SynlA andlor SERT
and other binding proteins.
Since it has been shown that p38 MAPK appears to be an intermediate step in the
PKG pathway, (Zhu, Carneiro et al. 2005) responsible for increases in 5-HT uptake in
heterologous cell systems, and inhibition ofp38 MAPK with a MAPK inhibitors blocks
5'rN-ethylcarboxamidoadenosine (NECA) stimulation of A3 adenosine receptors and
downstream increases in SERT activity, (Zhu, Hewlett et al. 2004; Zhu, Carneiro et al.
2005) we decided to explore whether or not activation ofp38 MAPK affected
oligomerization ofSERT. p38 MAPK activation has been found to increase SERT Vmax
without creating a change in SERT surface expression rendering p38 MAPK to regulate
SERT in a trafficking-independent matter (Samuvel, Jayanthi et al. 2005). In our studies
activation ofp38 MAPK by MKK3 increased SERT uptake and decreased SERT
oligomerization, an effect that could be blocked by the p38 MAPK inhibitor P0169316.
HEK-293 cells transfected with MKK3 and blocked by the p38 MAPK inhibitor
PO 169316 expressed levels of oligomerization that were comparable to controls.
Interestingly, incubation in the control condition of wild-type SERT with the p38 MAPK
inhibitor PO 169316 increased oligomerization without further activation of p3 8 MAPK
but produced no detectable change in eH]5-HT uptake. The latter data possibly point to
the ability ofp38 MAPK to basally phosphorylate SERT in native cells. This basal
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phosphorylation appears to be necessary for the proper insertion of SERT into the plasma
membrane as inhibition ofp38 MAPK with PD169316 decreases SERT expression in
surface biotinylated fractions in rat midbrain synaptosomes with a concomitant decrease
in 5-HT uptake (Samuvel, Jayanthi et al. 2005). Basal phosphorylation of SERT is not
controlled by PKC, Protein Kinase A (PKA), Calcium-calmodulin kinase 2 (CamK), or
Ca2+ chelation (Ramamoorthy, Giovanetti et al. 1998). Therefore, it is possible that this
inhibition ofp38 MAPK causes an increase in the oligomerization ofSERT that causes
SERT to remain internalized creating a negative feedback mechanism perhaps necessary
to control SERT uptake during times of low extracellular concentrations of 5-HT or times
when serotonergic signaling is weaker than normal. However, p38 MAPK is
characterized as a stress-activated protein kinase (SAPK) and has been shown to be
activated by environmental stressors such as anisomycin, H202, UV radiation (Zhu,
Carneiro et al. 2005), hypoxia, ischemia, ischemialreperfusion (RJ. 1994; Cano E 1995),
and inflammatory cytokines such as Tumor Necrosis Factor Alpha (TNF-u) (Liu Z. G.
1996). Therefore activation ofp38 MAPK by one or more of these "stressors" may cause
an increase in plasma membrane expression of SERT, which could be necessary to gather
extracellular 5-HT molecules that potentially could be degraded by activation of
molecules that breakdown monoamines (i.e. inflammatory cytokines, monoamine
oxidases, and cellular proteases). Therefore if a decrease in oligomerization is necessary
to increase uptake in times of stress, it has fathomable that in tiines of low stress,
oligomerization increases. Also it should be noted that it has been reported that
inhibition ofp38 MAPK decreases SERT/SynlA association with a concomitant decrease
in 5-HT uptake in midbrain synaptosomes (Samuvel, Jayanthi
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et al. 2005) adding further

support that SERT binding proteins may be necessary components for modifying the
oligomerization state of SERT.
We also saw that activation ofPKC, by the phorbol ester fJ-PMA, increased
association of SERT homo-oligomers in HEK-293 cells. PKC activation has been found
to decrease SERT activity by internalizing it from the plasma membrane (Ramamoorthy,
Giovanetti et al. 1998; Ramamoorthy and Blakely 1999; Vaughan 2004). Samuvel et al
(2005) showed that SERT was inserted into the plasma membrane by p38 MAPK and
internalized by PKC (Samuvel, Jayanthi et al. 2005). The inhibition ofp38 MAPK by
either siRNA constructs directed at p38 MAPK or the compound PD169316 decreased
uptake of 5-HT by SERT but by a different mechanism than PKC. p38 MAPK inhibition
decreased plasma membrane insertion compared to PKC's effect of increasing SERT
endocytosis (Samuvel, Jayanthi et al. 2005). It is possible that PKC's ability to increase
oligomerization may be an intracellular signal for increasing endocytosis of SERT.
Support for this arises from other systems that show activation of PKC increases
oligomerization of various proteins. For example, phosphorylation of Ezrin-RadixinMoesin (ERM) binding phosphoprotein 50 (EBP50), a scaffolding protein essential for
the localization and coordinated activity of apical transporters in endothelial cells, by
PKC increases EBP50 oligomerization (Fouassier, Nichols et al. 2005). Also, activation
ofPKC increases oligomerization of transmembrane proteoglycan syndecan-4, which is a
co-receptor with integrins in cytoskeleton-matrix interaction (Oh, Woods et al. 1997).
While these studies speak to increases in oligomerization with activation of PKC, they do
not discuss changes in activity or trafficking of the specific proteins. To our knowledge
this is the first paper that discusses changes in oligomerization of transporters by
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activation of protein kinases. One possible mechanism behind decreased PKC activity
with concomitant increased oligomerization is its possible association with SERT binding
proteins. One such protein is Secretory Carrier Membrane Protein 2 (SCAMP2) which
has been found to associate with SERT in both rat brain tissue and transfected HEK-293
cells and this association appears to reduce SERT activity in a trafficking-dependent
manner (Muller, Wiborg et al. 2006). Another SERT binding protein, Hic-5 is a multiple
LIM-domain protein previously thought to be a DAT-interacting protein found in the
brain that is not only found in neurons, but also in platelets, an area high in 5-HT and
SERT expression. Another possible protein that interacts with SERT is myristoylated
alanine-rich Ckinase substrate (MacMarcks) (Jess, El Far et al. 2002). Upon PKC
activation MacMarcks is translocated from intracellular compartments to the plasma
membrane where it interacts with the C-terminal tail of SERT where it plays a central
role in regulating SERT trafficking. Interestingly, interaction of SERT with MacMarcks
upon PKC activation causes an approximate 30% decrease in 5-HT uptake compared to
uptake with

~-PMA

itself. It is possible that upon PKC activation SERT oligomerizes

(possibly through the exposure of previously unavailable oligomerization sites), and
binding proteins like the ones mentioned above are recruited to the plasma membrane to
aid in internalization of SERT. Once SERT is internalized it is dephosphorylated by
protein phosphatases PP1/PP2A (Ramamoorthy, Giovanetti et al. 1998; Bauman,
Apparsundaram et al. 2000) which may cause these binding proteins to dissociate from
SERT allowing SERT to either recycle back to the plasma membrane, stored in
intracellular vesicles, or be targeted for degradation.

80

Research in receptor oligomerization adds support to the claim that
phosphorylation can affect protein oligomerization. For example phosphorylation of
small heat shock/alpha-crystallin proteins, heat shock proteins 23 and 70 (hsp 23 and
hsp70, protective against cardiac ischemia damage), by stress-responsive cascades
including MAPKAP kinase 2/3 and p38 has been shown to form smaller oligomeric
processes compared to nonphosphorylated hsp proteins (Martin, Hickey et al. 1999;
MacRae 2000). Also phosphorylation ofhsp25, which has been shown to be protective
against TNFa- or H2 0 2-mediated cytotoxicity, by p38 MAPK also showed smaller
oligomeric processes as above. In contrast, increased activation of PKC in painful
diabetic neuropathy causes an increase in oligomerization of the vanilloid receptor 1
(VRl) associated with inflammation and injury-induced pain (Hong and Wiley 2005).
Another study showed that activation of PKC by UV stimulation of mitochondrial
reactive oxygen species (mROS) increased translocation of Bax to mitochondria where
oligomerization was promoted and increased apoptotic cell death in MCF-7 breast cancer
cells (Pedram, Razandi et al. 2006). Lastly, oligomerization of AoHex 1, the major
protein of the woronin body, a specialized peroxisome involved in septal pore sealing and
protecting filamentous fungus from excessive cytoplasmic bleeding, increased with PKC
activation while inhibitors of PKC, bisindolylamaleimide I and chelerythrine, resulted in
a reduction of AoHex 1 oligomerization (Juvvadi, Maruyama et al. 2007). Interestingly
activation of cAMP-dependent kinase (PKA) shows no change in oligomerization state of
vasodilator-stimulated phosphoprotein (VASP) associated with promoting actin
nucleation, a kinase that is thought to exert its effects on SERT through a long-term,
chronic regulation of gene expression (Lawrence, Comerford et al. 2002). This may be
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of relevance because it appears that PKA exerts its' effects on SERT in a chronic fashion
that causes changes in SERT gene expression (Cool, Leibach et al. 1991; Ramamoorthy,
Ramamoorthy et al. 1995). This is in direct contrast to kinases such as PKG, p38 MAPK,
and PKC, all of which appear to exert their effects on SERT in an acute fashion, by
regulating uptake and surface expression. This data helps support that different protein
kinase activations can affect protein oligomerization. However, our experiments for the
first time show these effects in the serotonin transporter.
Since we have shown that activation ofkinases that increase SERT activity
decrease SERT oligomerization (PKG and p38 MAPK) and activation ofkinases that
decrease SERT activity increase SERT oligomerization, we decided to study ifSERT
phosphorylation is necessary for SERT oligomerization. To do this we created point
mutations at the known PKG phosphorylation site Thr276, T276A and T276D, as we
have previously shown (Ramamoorthy, Samuvel et al. 2007). Alanine mutation at the
site of phosphorylation (T276A) allows one to mimic a "non-phosphorylatable"
transporter at that site and mutation to aspartic acid (T276D) theoretically creates a
"constitutively activated" SERT. Our mutation studies revealed that mutation to either
alanine or aspartic acid created a decrease in SERT oligomerization compared to wildtype controls. While we expected to see the decrease in oligomerization present in the
T276D mutant, since it mimics our earlier findings that PKG activation decreases SERT
oligomerization, it was interesting to find that T276A also caused a decrease in
oligomerization. There are a couple possibilities why this may have occurred. 1) It is
possible that mutation ofThr 276 to alanine creates a structural change in SERT itself
that does not allow the transporter to properly oligomerize. 2) Mutation to alanine causes
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a change in the molecular forces that govern the second intracellular loop and could cause
an effect that changes oligomerization from wild-type. 3) It is possible that T276A
blocks partial phosphorylation of SERT but not all. Our lab has previously shown that
basal phosphorylation of SERT can partially be contributed to constitutive
phosphorylation by p38 MAPK (Samuvel, Jayanthi et al. 2005). Data we have collected
(unpublished results) show that p38 MAPK phosphorylates SERT not only at Thr276 but
at another putative phosphorylation site as well. Since we have shown here that
activation ofp38 MAPK decreases SERT oligomerization, it may be possible that the
phosphorylation of this site is causing the slight but significant decrease in
oligomerization we discovered in our current experiments. p38 MAPK is endogenously
expressed in HEK-293 cells (Nagao, Yamauchi et al. 1998; Hou, Ye et al. 2004) so it is
feasible that this latter possibility has some merit. To support this idea we decided to cotransfect His6-WT-SERT with either HA-WT-SERT + MKK3 or HA-T276A-SERT with
MKK3. Here it appeared that the T276A mutation caused a slight decrease in
oligomerization as in Figure l-SB but was not able to block the decrease in SERT
oligomerization when it was co-transfected with MKK3, Fig 1-7. Therefore, it appears
that p38 MAPK is not solely dependent on Thr276, at least for its oligomerization effect,
and this may help explain why co-transfection of T276A with MKK3 does not inhibit
decreased SERT oligomerization. This data also sheds some light to support that while
activation ofPKG and p38 MAPK lead to increased SERT activity the mechanisms of
how this occurs may be different. We have shown that there is no change in SERT
trafficking upon PKG activation with 8-Br-cGMP (Ramamoorthy, Samuvel et al. 2007)
but as previously mentioned, inhibition of p3 8 MAPK with PD 169316 decreases
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insertion of SERT into the plasma membrane (Samuvel, J ayanthi et al. 2005). Therefore,
the difference we experienced in oligomerization with T276A + 8-Br-cGMP in PKG and
p38 MAPK could also possibly be contributed to SERT trafficking differences.
We also decided to investigate the role of human polymorphisms that have been
found in clinical screenings of patients and have been to have co-morbity with obsessivecompulsive disorder (OCD), and to a lesser extent; Asperger's syndrome, social phobia,
anorexia nervosa, diabetic disorders, and alcohol and other substance abuse/dependence
(Ozaki N,

* Goldman D et al. 2003)

The two mutants we studied, Is0425Vai (I425V)

and Gly56Ala (G56A) have both been shown to increase SERT uptake with no further
increase in uptake with co-incubation of cGMP cell-permeable analogs (Kilic, Murphy et
al. 2003). Since these mutations appear to increase SERT activity, much like activation
ofPKG, p38 MAPK, and the SERT mutant T276D, we decided to assess I425V and
G56A mutations with SERT association. Our results showed that HEK-293 cells cotransfected with either HIS-WT-SERT + HA-I425V-SERT or HIS-WT-SERT + HAG56A-SERT both showed an endogenous decrease in SERT oligomerization as analyzed
by Ni 2+ affinity chromatography compared to wild-type controls. These results are
similar to our earlier findings that PKG, p38 MAPK, and T276D decrease SERT
oligomerization. However, when HEK-293 cells were transfected with human mutant
conditions as above and treated with 8-Br-cGMP (IOflM, 15 minutes, 37°C), we observed
a significant decrease in oligomerization in cells transfected with G56A but not with
I425V. This is a curious finding because it has been shown previously that 8-Br-cGMP
does not further increase 5-HT uptake in cells transfected with I425V or G56A (Kilic,
Murphy et al. 2003). One possible explanation of these results is that mutation at these

84

sites could cause conformational changes that do not allow the PKG phosphorylation site
T276 to be readily available to PKG for phosphorylation. However, since these two
mutations lie on far spectrums of the SERT gene, it is possible that G56A (which lies in
the intracellular N-terminal region of SERT) and 1425V (that resides within the fourth
intracellular loop (IL4) between TM regions 8 and 9) may exert differing effects on the
SERT micro-environment. It is possible that mutation at I425V creates a microenvironment that is not able to allow phosphorylation ofT276 by PKG, while mutation at
G56A may not cause such a change in protein conformational shape. This explanation
may account for the lack of increased 5-HT uptake by I425V SERT as has been
previously reported (Kilic, Murphy et al. 2003).
N ext we looked to address the question if oligomerization of the human mutant
polymorphism I425V is dependent on proper folding, packaging, and exportation in the
endoplasmic reticulum. Our data showed that proteins that were not co-expressed in
HEK-293 cells and did not undergo ER processing together do not oligomerize as
evidenced by Ne+ affinity chromatography. Co-immunoprecipitation ofHIS-WT-SERT
+ HA-I425V-SERT in the co-transfected conditioned revealed that I425V is not a signal
for ER retention and is processed normally in the ER, while appearing to decrease total
SERT oligomerization compared to wild-type controls. Oligomerization has been
proposed in the ER as a mechanism for masking ER signal retention motifs within protein
monomers (Standley, Roche et al. 2000). Mutations within GAT-! at the leucine zipper
in TM2 results in proteins that are retained in the ER, however'! these mutants can still
perform uptake of GABA showing that they are correctly folded (Scholze, Freissmuth et
al. 2002). While we did not test uptake of 5-HT by wild-type and mutant I425V SERT in
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these experiments as this has been previously performed, our results showed that coexpression is necessary for SERT oligomerization. Also this data is supported in research
pertaining to G-protein couple receptors (GPCRs). The ER has been viewed as a quality
control mechanism for GPCRs in that monomer units of certain GPCRs. For example,
the metabotropic GABAB receptor. This receptor is made up of two subunits GbR 1 and
GbR2. When GbR 1 is expressed alone a signal sequence present in the C-terminal that is
coded for an ER retention signal causes retention of the subunit within the ER.
Oligomerization in the ER of GbRl with GbR2 causes the masking of the signal sequence
and the receptor is properly exported from the ER (Terrillon and Bouvier 2004).
However it is possible that oligomerization of GPCRs can also be regulated on the
plasma membrane and not just in the ER. Several studies have shown that ligand binding
can either promote (Rodriguez-Frade, Vila-Coro et al. 1999; Angers, Salahpour et al.
2000) or inhibit (Gines 2000; Cheng and Miller 2001) GPCR oligomerization. However,
it is relatively unknown if phosphorylation of GPCRs affects their oligomerization state.
Therefore while earlier studies have focused on the importance of oligomerization for ER
exportation we have showed the oligomerization is also necessary for functional
regulation of SERT. It is important in the future to also look at other proteins that
oligomerize and how they are affected by protein-kinase signaling cascades. The result
of this nlay allow researchers to possibly draw a common conclusion about the regulation
and effect of oligomerization in both receptors and transporters.
Lastly we chose to look at the effects of cocaine on SERT oligomerization. We
applied a range of cocaine concentrations [0-50

~M]

to HEK-293 cells transfected with

HIS-WT-SERT + HA-WT-SERT for 30 minutes at 37°C. We saw a significant increase
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in SERT oligomerization at the 7.5 11M cocaine concentration, which appears to be a
physiologically relevant cocaine dose (Peter Kalivas, Personal Communication) and has
been used in other studies studying cellular cocaine effects (Zhu MY et aI, 2000; Daws
LC et aI, 2002). Concentrations higher and lower than 7.5 11M did not show significant
increases in SERT oligomerization, but did show a trend of decreased oligomerization in
higher concentrations which are most likely due to problems with cell toxicity. Cocaine
is a drug that targets the monoamine transporters: SERT, DAT, and NET, with a high
affinity for SERT and DAT. It acts as a reuptake inhibitor in that it binds to these
transporters and blocks transporter-mediated reuptake of transmitter molecules from the
synapse. This in tum can elevate extracellular transmitter concentrations and cause a
wide variety of effects including paranoid ideation and psychosis (Gawin and Kleber
1986). Chang and colleagues have showed that cocaine-binding occurs with equal
affinity to SERT monomers, dimers, trimers, and tetramers, while only monomers,
dimers, and tetramers revealed significant 5-HT uptake (Chang et al 1998). Therefore it
is feasible that cocaine can bind to any possible oligomeric state of SERT and possibly
have an effect on its oligomerization. Another study in DAT found that DAT expression
in irradiated striatal membrane preparations was proposed to be a homo- or heterooligomer when occupied in situ by uptake-blocking drugs such as cocaine (Berger SP et
al 1994). Support from receptor studies helps show that cocaine may indeed induce
increase in protein oligomerization. An example of this was a study by Xi et al 2002 that
showed treatment of rats with injected cocaine daily after extinction for 1 and 3 weeks
showed elevations of the mGluR2/3 dimer in the nucleus accumbens and the prefrontal
cortex (PFC) with a reduction in the monomer in PFC only (XI, Ramamoorthy et al.
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2002). Also as previously mentioned, studies have shown that oligomerization of GPCRs
is increased due to ligand binding (Rodriguez-Frade, Vila-Coro et al. 1999; Angers,
Salahpour et al. 2000). It is possible that one of cocaine's modes of function is to
decrease monoamine uptake by increasing oligomerization instead of blocking the
translo'cation pore. Acute cocaine administration has been shown to increase DAT
(Zahniser and Sorkin 2004) surface expression which is in direct contrast to PKCmediated decreases in SERT plasma membrane expression (Ramamoorthy, Giovanetti et
al. 1998). Research on cocaine's effect on cGMP levels has been debated. For example
it has been found to decrease levels of cGMP in that rat ventral tagmental area upon
injection (Jouvert P et ai, 2004) but it has been shown to increase intracellular cGMP
concentrations in other rat brain structures (Macedo DS et ai, 2001) and heterologous cell
systems (Yang Y et ai, 2001). However these latter studies were conducted in rat
prefrontal cortex and through muscarinic receptors in HEL299 cells, respectively.
Therefore, it is possible that cocaine may have exert different effects on cGMP levels
depending on the brain area or cell system that is used. It is possible that while both
(cocaine, and PKC) increase SERT oligomerization that they cause SERT to undergo
different trafficking pathways with respect to surface expression.
While in our experiments both p.. PMA (for PKC activation) and cocaine were pre..
incubated with HEK.. 293 cells for 30 minutes at 37°C. These two, PKC and cocaine, have
been predicted to bind at different sites within the transporter. While the PKC binding
site is unknown it is thought to be an internal site within SERT (Ramamoorthy, Bauman
et al. 1993). The cocaine binding site is exposed to the extracellular milieu and thought
to be a separate binding site then the anti-depressant extracellular binding site, both of
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which are under location speculation (Rothman RB, 1999b). However it is speculated
that both PKC and cocaine bind multiple sites within SERT and therefore it is difficult to
state which sites are responsible for oligomerization and/or internalization. It is
interesting though that administration of drugs of abuse that are substrates for SERT (e.g.
amphetamine and methylphenidate) have been shown to increase transporter
internalization, in direct contrast of cocaine's effect of increasing transporter plasma
membrane expression (Boot, Meehan et al. 2002; Xie, Tong et al. 2006). They have also
been found to both be activators ofPKC.(Kramer, Poblete et al. 1997; Hsieh, Yang et al.
2005; Xie and Miller 2007) allowing a connection to be made between the effects of
amphetamine and PKC, both of which cause an internalization ofSERT. Also, PKC
activation or ampthetamine treatment ofHEK-293 cells transiently and stably transfected
with DA T showed increases in FRET signaling in endosomes, indicative of efficient
oligomerization of internalized DAT (Sorkina, Doolen et al. 2003). It is also possible
that cocaine may exert its effect on protein kinases that in tum may affect SERT
oligomerization, because cocaine's principal target is the SERT protein itself this may not
be feasible. Therefore it is possible that these two processes, PKC activation and cocaine
binding, while both causing increases in oligomerization, due to different sites of
interaction may cause differing alterations in SERT trafficking.

Taken together the present data show that phosphorylation of SERT or mutations
within SERT have a profound effect on SERT oligomerization. While we cannot
definitely say that a gain or loss of quaternary structure in oligomerization causes
changes in SERT uptake, we can state that for the first time that kinases that have been
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shown to increase SERT uptake of 5-HT (PKG and p38 MAPK) decrease SERT
oligomerization and a kinase that has been shown to decrease 5-HT uptake (PKC) results
in an increase in SERT oligomerization. Other studies performed have looked at mainly
mutational methods to show that SERT exists as an oligomer but this is the first time that
SERT oligomerization has been found to be a consequence of protein kinase-protein
association with SERT. While our findings shed some light into the process ofSERT
oligomerization several questions still remain to be asked. First, where does
oligomerization occur in the cell? It has been hypothesized that oligomerization occurs
in the ER during the folding process and is necessary for plasma membrane insertion
(Farhan, Reiterer et al. 2007). However there has been no data reported that speaks to
affecting oligomerization of SERT outside of the ER even though it has been thought to
be necessary for ER export. Are there other kinases or inhibition of phosphatases that
possibly could cause changes in SERT oligomerization? For example, PP1/PP2A
inhibitors such as okadaic acid have been found to decrease SERT activity with
concomitant down-regulation ofSERT (Ramamoorthy, Giovanetti et al. 1998; Bauman,
Apparsundaram et al. 2000; Bauman, Apparsundaram et al. 2000). Also kinases such as
protein kinase A (PKA) (Ramamoorthy, Ramamoorthy et al. 1995), and CalmodulinDependent Kinase II (CamKII) (Jayanthi, Ramamoorthy et al. 1994), have been found to
have effects on SERT activity and gene expression as well. What are the effects of
chronically activated kinases such as PKA on SERT oligomerization? Lastly, what role
does 1425V's and G56A;s effect on oligomerization play in human disease? Overall, this
study opens new doors for future transporter research. With recent crystalizing of the
Leur bacterial homologue transporter (Yamashita, Singh et al. 2005) and subsequent
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follow-up papers (Beuming, Shi et al. 2006; Ravna, Jaronczyk et al. 2006), we now have
a greater understanding of the three-dimensional topography of SERT. With this
knowledge we can probe into the underpinnings that regulate oligomerization and
identify not only the sites but also the mechanisms underlying this dynamic process.
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